1
|
de Sousa TR, Dt C, Novais F. Exploring the Hypothesis of a Schizophrenia and Bipolar Disorder Continuum: Biological, Genetic and Pharmacologic Data. CNS & NEUROLOGICAL DISORDERS DRUG TARGETS 2023; 22:161-171. [PMID: 34477537 DOI: 10.2174/1871527320666210902164235] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Revised: 07/19/2021] [Accepted: 08/08/2021] [Indexed: 12/16/2022]
Abstract
Present time nosology has its roots in Kraepelin's demarcation of schizophrenia and bipolar disorder. However, accumulating evidence has shed light on several commonalities between the two disorders, and some authors have advocated for the consideration of a disease continuum. Here, we review previous genetic, biological and pharmacological findings that provide the basis for this conceptualization. There is a cross-disease heritability, and they share single-nucleotide polymorphisms in some common genes. EEG and imaging patterns have a number of similarities, namely reduced white matter integrity and abnormal connectivity. Dopamine, serotonin, GABA and glutamate systems have dysfunctional features, some of which are identical among the disorders. Finally, cellular calcium regulation and mitochondrial function are, also, impaired in the two.
Collapse
Affiliation(s)
- Teresa Reynolds de Sousa
- Department of Neurosciences and Mental Health, Centro Hospitalar Universitário Lisboa Norte (CHULN), Hospital de Santa Maria, Lisbon, Portugal
| | - Correia Dt
- Department of Neurosciences and Mental Health, Centro Hospitalar Universitário Lisboa Norte (CHULN), Hospital de Santa Maria, Lisbon, Portugal
- Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
- ISAMB - Instituto de Saúde Ambiental, Lisboa, Portugal
| | - Filipa Novais
- Department of Neurosciences and Mental Health, Centro Hospitalar Universitário Lisboa Norte (CHULN), Hospital de Santa Maria, Lisbon, Portugal
- Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
- ISAMB - Instituto de Saúde Ambiental, Lisboa, Portugal
| |
Collapse
|
2
|
León-Ortiz P, Reyes-Madrigal F, Kochunov P, Gómez-Cruz G, Moncada-Habib T, Malacara M, Mora-Durán R, Rowland LM, de la Fuente-Sandoval C. White matter alterations and the conversion to psychosis: A combined diffusion tensor imaging and glutamate 1H MRS study. Schizophr Res 2022; 249:85-92. [PMID: 32595100 PMCID: PMC10025976 DOI: 10.1016/j.schres.2020.06.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Revised: 06/08/2020] [Accepted: 06/10/2020] [Indexed: 12/14/2022]
Abstract
INTRODUCTION Widespread white matter abnormalities and alterations in glutamate levels have been reported in patients with schizophrenia. We hypothesized that alterations in white matter integrity and glutamate levels in individuals at clinical high risk (CHR) for psychosis are associated with the subsequent development of psychosis. METHODS Participants included 33 antipsychotic naïve CHR (Female 7/Male 26, Age 19.55 (4.14) years) and 38 healthy controls (Female 10/Male 28, Age 20.92 (3.37) years). Whole brain diffusion tensor imaging for fractional anisotropy (FA) and right frontal white matter proton magnetic resonance spectroscopy for glutamate levels were acquired. CHR participants were clinically followed for 2 years to determine conversion to psychosis. RESULTS CHR participants that transitioned to psychosis (N = 7, 21%) were characterized by significantly lower FA values in the posterior thalamic radiation compared to those who did not transition and healthy controls. In the CHR group that transitioned to psychosis only, positive exploratory correlations between glutamate levels and FA values of the posterior thalamic radiation and the retrolenticular part of the internal capsule and a negative correlation between glutamate levels and the cingulum FA values were found. CONCLUSION The results of the present study highlight that alterations in white matter structure and glutamate are related with the conversion to psychosis.
Collapse
Affiliation(s)
- Pablo León-Ortiz
- Laboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico; Department of Education, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
| | - Francisco Reyes-Madrigal
- Laboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
| | - Peter Kochunov
- Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, United States of America
| | - Gladys Gómez-Cruz
- Laboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
| | - Tomás Moncada-Habib
- Laboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
| | - Melanie Malacara
- Laboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
| | - Ricardo Mora-Durán
- Emergency Department, Hospital Fray Bernardino Álvarez, Mexico City, Mexico
| | - Laura M Rowland
- Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, United States of America
| | - Camilo de la Fuente-Sandoval
- Laboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico; Neuropsychiatry Department, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.
| |
Collapse
|
3
|
Vouga Ribeiro N, Tavares V, Bramon E, Toulopoulou T, Valli I, Shergill S, Murray R, Prata D. Effects of psychosis-associated genetic markers on brain volumetry: a systematic review of replicated findings and an independent validation. Psychol Med 2022; 52:1-16. [PMID: 36168994 PMCID: PMC9811278 DOI: 10.1017/s0033291722002896] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Revised: 08/13/2022] [Accepted: 08/24/2022] [Indexed: 01/12/2023]
Abstract
BACKGROUND Given psychotic illnesses' high heritability and associations with brain structure, numerous neuroimaging-genetics findings have been reported in the last two decades. However, few findings have been replicated. In the present independent sample we aimed to replicate any psychosis-implicated SNPs (single nucleotide polymorphisms), which had previously shown at least two main effects on brain volume. METHODS A systematic review for SNPs showing a replicated effect on brain volume yielded 25 studies implicating seven SNPs in five genes. Their effect was then tested in 113 subjects with either schizophrenia, bipolar disorder, 'at risk mental state' or healthy state, for whole-brain and region-of-interest (ROI) associations with grey and white matter volume changes, using voxel-based morphometry. RESULTS We found FWER-corrected (Family-wise error rate) (i.e. statistically significant) associations of: (1) CACNA1C-rs769087-A with larger bilateral hippocampus and thalamus white matter, across the whole brain; and (2) CACNA1C-rs769087-A with larger superior frontal gyrus, as ROI. Higher replication concordance with existing literature was found, in decreasing order, for: (1) CACNA1C-rs769087-A, with larger dorsolateral-prefrontal/superior frontal gyrus and hippocampi (both with anatomical and directional concordance); (2) ZNF804A-rs11681373-A, with smaller angular gyrus grey matter and rectus gyri white matter (both with anatomical and directional concordance); and (3) BDNF-rs6265-T with superior frontal and middle cingulate gyri volume change (with anatomical and allelic concordance). CONCLUSIONS Most literature findings were not herein replicated. Nevertheless, high degree/likelihood of replication was found for two genome-wide association studies- and one candidate-implicated SNPs, supporting their involvement in psychosis and brain structure.
Collapse
Affiliation(s)
- Nuno Vouga Ribeiro
- Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
- Instituto de Biofísica e Engenharia Biomédica, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal
| | - Vânia Tavares
- Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
- Instituto de Biofísica e Engenharia Biomédica, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal
| | - Elvira Bramon
- Division of Psychiatry, University College London, London, UK
- Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’ College London, London, UK
- Institute of Cognitive Neuroscience, University College London, London, UK
| | - Timothea Toulopoulou
- Department of Psychology & National Magnetic Resonance Research Center (UMRAM), Aysel Sabuncu Brain Research Centre (ASBAM), Bilkent University, Ankara, Turkey
| | - Isabel Valli
- Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’ College London, London, UK
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - Sukhi Shergill
- Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’ College London, London, UK
| | - Robin Murray
- Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’ College London, London, UK
| | - Diana Prata
- Instituto de Biofísica e Engenharia Biomédica, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal
- Department of Old Age Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| |
Collapse
|
4
|
Sustained ErbB Activation Causes Demyelination and Hypomyelination by Driving Necroptosis of Mature Oligodendrocytes and Apoptosis of Oligodendrocyte Precursor Cells. J Neurosci 2021; 41:9872-9890. [PMID: 34725188 PMCID: PMC8638686 DOI: 10.1523/jneurosci.2922-20.2021] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Revised: 09/27/2021] [Accepted: 10/24/2021] [Indexed: 11/26/2022] Open
Abstract
Oligodendrocytes are vulnerable to genetic and environmental insults and its injury leads to demyelinating diseases. The roles of ErbB receptors in maintaining the CNS myelin integrity are largely unknown. Here, we overactivate ErbB receptors that mediate signaling of either neuregulin (NRG) or epidermal growth factor (EGF) family growth factors and found their synergistic activation caused deleterious outcomes in white matter. Sustained ErbB activation induced by the tetracycline-dependent mouse tool Plp-tTA resulted in demyelination, axonal degeneration, oligodendrocyte precursor cell (OPC) proliferation, astrogliosis, and microgliosis in white matter. Moreover, there was hypermyelination before these inflammatory pathologic events. In contrast, sustained ErbB activation induced by another tetracycline-dependent mouse tool Sox10+/rtTA caused hypomyelination in the corpus callosum and optic nerve, which appeared to be a developmental deficit and did not associate with OPC regeneration, astrogliosis, or microgliosis. By tracing the differentiation states of cells expressing tetracycline-controlled transcriptional activator (tTA)/reverse tTA (rtTA)-dependent transgene or pulse-labeled reporter proteins in vitro and in vivo, we found that Plp-tTA targeted mainly mature oligodendrocytes (MOs), whereas Sox10+/rtTA targeted OPCs and newly-formed oligodendrocytes (NFOs). The distinct phenotypes of mice with ErbB overactivation induced by Plp-tTA and Sox10+/rtTA consolidated their nonoverlapping targeting preferences in the oligodendrocyte lineage, and enabled us to demonstrate that ErbB overactivation in MOs induced necroptosis that caused inflammatory demyelination, whereas in OPCs induced apoptosis that caused noninflammatory hypomyelination. Early interference with aberrant ErbB activation ceased oligodendrocyte deaths and restored myelin development in both mice. This study suggests that aberrant ErbB activation is an upstream pathogenetic mechanism of demyelinating diseases, providing a potential therapeutic target. SIGNIFICANCE STATEMENT Primary oligodendropathy is one of the etiologic mechanisms for multiple sclerosis, and oligodendrocyte necroptosis is a pathologic hallmark in the disease. Moreover, the demyelinating disease is now a broad concept that embraces schizophrenia, in which white matter lesions are an emerging feature. ErbB overactivation has been implicated in schizophrenia by genetic analysis and postmortem studies. This study suggests the etiologic implications of ErbB overactivation in myelin pathogenesis and elucidates the pathogenetic mechanisms.
Collapse
|
5
|
Duan J, Wei Y, Womer FY, Zhang X, Chang M, Zhu Y, Liu Z, Li C, Yin Z, Zhang R, Sun J, Wang P, Wang S, Jiang X, Wei S, Zhang Y, Tang Y, Wang F. Neurobiological substrates of major psychiatry disorders: transdiagnostic associations between white matter abnormalities, neuregulin 1 and clinical manifestation. J Psychiatry Neurosci 2021; 46:E506-E515. [PMID: 34467747 PMCID: PMC8526153 DOI: 10.1503/jpn.200166] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND Schizophrenia, bipolar disorder and major depressive disorder are increasingly being conceptualized as a transdiagnostic continuum. Disruption of white matter is a common alteration in these psychiatric disorders, but the molecular mechanisms underlying the disruption remain unclear. Neuregulin 1 (NRG1) is genetically linked with susceptibility to schizophrenia, bipolar disorder and major depressive disorder, and it is also related to white matter. METHODS Using a transdiagnostic approach, we aimed to identify white matter differences associated with NRG1 and their relationship to transdiagnostic symptoms and cognitive function. We examined the white matter of 1051 participants (318 healthy controls and 733 patients with major psychiatric disorders: 254 with schizophrenia, 212 with bipolar disorder and 267 with major depressive disorder) who underwent diffusion tensor imaging. We measured the plasma NRG1-β1 levels of 331 participants. We also evaluated clinical symptoms and cognitive function. RESULTS In the patient group, abnormal white matter was negatively associated with NRG1-β1 levels in the genu of the corpus callosum, right uncinate fasciculus, bilateral inferior fronto-occipital fasciculus, right external capsule, fornix, right optic tract, left straight gyrus white matter and left olfactory radiation. These NRG1-associated white matter abnormalities were also associated with depression and anxiety symptoms and executive function in patients with a major psychiatric disorder. Furthermore, across the 3 disorders we observed analogous alterations in white matter, NRG1-β1 levels and clinical manifestations. LIMITATIONS Medication status, the wide age range and our cross-sectional findings were limitations of this study. CONCLUSION This study is the first to provide evidence for an association between NRG1, white matter abnormalities, clinical symptoms and cognition in a transdiagnostic psychiatric cohort. These findings provide further support for an understanding of the molecular mechanisms that underlie the neuroimaging substrates of major psychiatric disorders and their clinical implications.
Collapse
Affiliation(s)
- Jia Duan
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Yange Wei
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Fay Y Womer
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Xizhe Zhang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Miao Chang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Yue Zhu
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Zhuang Liu
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Chao Li
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Zhiyang Yin
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Ran Zhang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Jiaze Sun
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Pengshuo Wang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Shuai Wang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Xiaowei Jiang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Shengnan Wei
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Yanbo Zhang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Yanqing Tang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Fei Wang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| |
Collapse
|
6
|
Klein PC, Ettinger U, Schirner M, Ritter P, Rujescu D, Falkai P, Koutsouleris N, Kambeitz-Ilankovic L, Kambeitz J. Brain Network Simulations Indicate Effects of Neuregulin-1 Genotype on Excitation-Inhibition Balance in Cortical Dynamics. Cereb Cortex 2021; 31:2013-2025. [PMID: 33279967 DOI: 10.1093/cercor/bhaa339] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Revised: 09/01/2020] [Accepted: 10/11/2020] [Indexed: 11/14/2022] Open
Abstract
Neuregulin-1 (NRG1) represents an important factor for multiple processes including neurodevelopment, brain functioning or cognitive functions. Evidence from animal research suggests an effect of NRG1 on the excitation-inhibition (E/I) balance in cortical circuits. However, direct evidence for the importance of NRG1 in E/I balance in humans is still lacking. In this work, we demonstrate the application of computational, biophysical network models to advance our understanding of the interaction between cortical activity observed in neuroimaging and the underlying neurobiology. We employed a biophysical neuronal model to simulate large-scale brain dynamics and to investigate the role of polymorphisms in the NRG1 gene (rs35753505, rs3924999) in n = 96 healthy adults. Our results show that G/G-carriers (rs3924999) exhibit a significant difference in global coupling (P = 0.048) and multiple parameters determining E/I-balance such as excitatory synaptic coupling (P = 0.047), local excitatory recurrence (P = 0.032) and inhibitory synaptic coupling (P = 0.028). This indicates that NRG1 may be related to excitatory recurrence or excitatory synaptic coupling potentially resulting in altered E/I-balance. Moreover, we suggest that computational modeling is a suitable tool to investigate specific biological mechanisms in health and disease.
Collapse
Affiliation(s)
- Pedro Costa Klein
- Department of Psychiatry, University of Cologne, Faculty of Medicine and University Hospital Cologne, 50937, Germany
| | - Ulrich Ettinger
- Department of Psychology, University of Bonn, Bonn, 53111, Germany
| | - Michael Schirner
- Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Dept. of Neurology, 10117, Germany.,Bernstein Focus State Dependencies of Learning & Bernstein Center for Computational Neuroscience, Berlin 10115, Germany
| | - Petra Ritter
- Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Dept. of Neurology, 10117, Germany.,Bernstein Focus State Dependencies of Learning & Bernstein Center for Computational Neuroscience, Berlin 10115, Germany
| | - Dan Rujescu
- University Clinic for Psychiatry, Psychotherapy and Psychosomatic, Martin-Luther-University, Halle-Wittenberg, 06112, Germany
| | - Peter Falkai
- Department of Psychiatry, Ludwig Maximilians Universität München, 80336, Germany
| | | | - Lana Kambeitz-Ilankovic
- Department of Psychiatry, University of Cologne, Faculty of Medicine and University Hospital Cologne, 50937, Germany.,Department of Psychiatry, Ludwig Maximilians Universität München, 80336, Germany
| | - Joseph Kambeitz
- Department of Psychiatry, University of Cologne, Faculty of Medicine and University Hospital Cologne, 50937, Germany
| |
Collapse
|
7
|
Gouvêa-Junqueira D, Falvella ACB, Antunes ASLM, Seabra G, Brandão-Teles C, Martins-de-Souza D, Crunfli F. Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia. Front Psychiatry 2020; 11:379. [PMID: 32425837 PMCID: PMC7203658 DOI: 10.3389/fpsyt.2020.00379] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Accepted: 04/15/2020] [Indexed: 12/12/2022] Open
Abstract
Oligodendrocytes are the glial cells responsible for the formation of the myelin sheath around axons. During neurodevelopment, oligodendrocytes undergo maturation and differentiation, and later remyelination in adulthood. Abnormalities in these processes have been associated with behavioral and cognitive dysfunctions and the development of various mental illnesses like schizophrenia. Several studies have implicated oligodendrocyte dysfunction and myelin abnormalities in the disorder, together with altered expression of myelin-related genes such as Olig2, CNP, and NRG1. However, the molecular mechanisms subjacent of these alterations remain elusive. Schizophrenia is a severe, chronic psychiatric disorder affecting more than 23 million individuals worldwide and its symptoms usually appear at the beginning of adulthood. Currently, the major therapeutic strategy for schizophrenia relies on the use of antipsychotics. Despite their widespread use, the effects of antipsychotics on glial cells, especially oligodendrocytes, remain unclear. Thus, in this review we highlight the current knowledge regarding oligodendrocyte dysfunction in schizophrenia, compiling data from (epi)genetic studies and up-to-date models to investigate the role of oligodendrocytes in the disorder. In addition, we examined potential targets currently investigated for the improvement of schizophrenia symptoms. Research in this area has been investigating potential beneficial compounds, including the D-amino acids D-aspartate and D-serine, that act as NMDA receptor agonists, modulating the glutamatergic signaling; the antioxidant N-acetylcysteine, a precursor in the synthesis of glutathione, protecting against the redox imbalance; as well as lithium, an inhibitor of glycogen synthase kinase 3β (GSK3β) signaling, contributing to oligodendrocyte survival and functioning. In conclusion, there is strong evidence linking oligodendrocyte dysfunction to the development of schizophrenia. Hence, a better understanding of oligodendrocyte differentiation, as well as the effects of antipsychotic medication in these cells, could have potential implications for understanding the development of schizophrenia and finding new targets for drug development.
Collapse
Affiliation(s)
- Danielle Gouvêa-Junqueira
- Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - Ana Caroline Brambilla Falvella
- Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - André Saraiva Leão Marcelo Antunes
- Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - Gabriela Seabra
- Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - Caroline Brandão-Teles
- Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas, Campinas, Brazil
| | - Daniel Martins-de-Souza
- Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas, Campinas, Brazil
- Experimental Medicine Research Cluster (EMRC), University of Campinas, Campinas, Brazil
- Instituto Nacional de Biomarcadores em Neuropsiquiatria, Conselho Nacional de Desenvolvimento Científico e Tecnológico, São Paulo, Brazil
- D′Or Institute for Research and Education (IDOR), São Paulo, Brazil
| | - Fernanda Crunfli
- Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas, Campinas, Brazil
| |
Collapse
|
8
|
Lautarescu A, Pecheva D, Nosarti C, Nihouarn J, Zhang H, Victor S, Craig M, Edwards AD, Counsell SJ. Maternal Prenatal Stress Is Associated With Altered Uncinate Fasciculus Microstructure in Premature Neonates. Biol Psychiatry 2020; 87:559-569. [PMID: 31604519 PMCID: PMC7016501 DOI: 10.1016/j.biopsych.2019.08.010] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2019] [Revised: 08/13/2019] [Accepted: 08/13/2019] [Indexed: 12/16/2022]
Abstract
BACKGROUND Maternal prenatal stress exposure (PNSE) increases risk for adverse psychiatric and behavioral outcomes in offspring. The biological basis for this elevated risk is poorly understood but may involve alterations to the neurodevelopmental trajectory of white matter tracts within the limbic system, particularly the uncinate fasciculus. Additionally, preterm birth is associated with both impaired white matter development and adverse developmental outcomes. In this study we hypothesized that higher maternal PNSE was associated with altered uncinate fasciculus microstructure in offspring. METHODS In this study, 251 preterm infants (132 male, 119 female) (median gestational age = 30.29 weeks [range, 23.57-32.86 weeks]) underwent brain magnetic resonance imaging including diffusion-weighted imaging around term-equivalent age (median = 42.43 weeks [range, 37.86-45.71 weeks]). Measures of white matter microstructure were calculated for the uncinate fasciculus and the inferior longitudinal fasciculus, a control tract that we hypothesized was not associated with maternal PNSE. Multiple regressions were used to investigate the relationship among maternal trait anxiety scores, stressful life events, and white matter microstructure indices in the neonatal brain. RESULTS Adjusting for gestational age at birth, postmenstrual age at scan, maternal age, socioeconomic status, sex, and number of days on parenteral nutrition, higher stressful life events scores were associated with higher axial diffusivity (β = .177, q = .007), radial diffusivity (β = .133, q = .026), and mean diffusivity (β = .149, q = .012) in the left uncinate fasciculus, and higher axial diffusivity (β = .142, q = .026) in the right uncinate fasciculus. CONCLUSIONS These findings suggest that PNSE is associated with altered development of specific frontolimbic pathways in preterm neonates as early as term-equivalent age.
Collapse
Affiliation(s)
- Alexandra Lautarescu
- Department of Perinatal Imaging and Health, Centre for Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom; Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
| | - Diliana Pecheva
- Department of Perinatal Imaging and Health, Centre for Developing Brain, School of Biomedical Engineering and Imaging Sciences, King’s College London, London, United Kingdom
| | - Chiara Nosarti
- Department of Perinatal Imaging and Health, Centre for Developing Brain, School of Biomedical Engineering and Imaging Sciences, King’s College London, London, United Kingdom
| | - Julie Nihouarn
- Department of Perinatal Imaging and Health, Centre for Developing Brain, School of Biomedical Engineering and Imaging Sciences, King’s College London, London, United Kingdom
| | - Hui Zhang
- Department of Computer Science and Centre for Medical Image Computing, University College London, London, United Kingdom
| | - Suresh Victor
- Department of Perinatal Imaging and Health, Centre for Developing Brain, School of Biomedical Engineering and Imaging Sciences, King’s College London, London, United Kingdom
| | - Michael Craig
- Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom,National Female Hormone Clinic, South London and Maudsley National Health Service Foundation Trust, London, United Kingdom
| | - A. David Edwards
- Department of Perinatal Imaging and Health, Centre for Developing Brain, School of Biomedical Engineering and Imaging Sciences, King’s College London, London, United Kingdom
| | - Serena J. Counsell
- Department of Perinatal Imaging and Health, Centre for Developing Brain, School of Biomedical Engineering and Imaging Sciences, King’s College London, London, United Kingdom
| |
Collapse
|
9
|
Mithani K, Davison B, Meng Y, Lipsman N. The anterior limb of the internal capsule: Anatomy, function, and dysfunction. Behav Brain Res 2020; 387:112588. [PMID: 32179062 DOI: 10.1016/j.bbr.2020.112588] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Revised: 12/22/2019] [Accepted: 02/28/2020] [Indexed: 12/22/2022]
Abstract
The last two decades have seen a re-emergence of neurosurgery for severe, refractory psychiatric diseases, largely due to the advent of more precise and safe operative techniques. Nevertheless, the optimal targets for these surgeries remain a matter of debate, and are often grandfathered from experiences in the late 20th century. To better explore the rationale for one target in particular - the anterior limb of the internal capsule (ALIC) - we comprehensively reviewed all available literature on its role in the pathophysiology and treatment of mental illness. We first provide an overview of its functional anatomy, followed by a discussion on its role in several prevalent psychiatric diseases. Given its structural integration into the limbic system and involvement in a number of cognitive and emotional processes, the ALIC is a robust target for surgical treatment of refractory psychiatric diseases. The advent of novel neuroimaging techniques, coupled with image-guided therapeutics and neuromodulatory treatments, will continue to enable study on the ALIC in mental illness.
Collapse
Affiliation(s)
- Karim Mithani
- Sunnybrook Research Institute, Toronto, Ontario, Canada
| | | | - Ying Meng
- Sunnybrook Research Institute, Toronto, Ontario, Canada
| | - Nir Lipsman
- Sunnybrook Research Institute, Toronto, Ontario, Canada.
| |
Collapse
|
10
|
Wang D, Guo T, Guo Q, Zhang S, Zhang J, Luo J. The Association Between Schizophrenia Risk Variants and Creativity in Healthy Han Chinese Subjects. Front Psychol 2019; 10:2218. [PMID: 31649580 PMCID: PMC6792478 DOI: 10.3389/fpsyg.2019.02218] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Accepted: 09/17/2019] [Indexed: 11/14/2022] Open
Abstract
Although previous evidence has suggested that there is a genetic link between schizophrenia and creativity, the specific genetic variants that underlie the link are still largely unknown. To further explore the potential genetic link between schizophrenia and creativity, in a sample of 580 healthy Han Chinese subjects, this study aimed to (1) validate the role of Neuregulin 1 (NRG1) rs6994992 (one schizophrenia risk variant that has been previously linked to creativity in the European population) in the relationship between schizophrenia and creativity and (2) explore the associations between 10 other schizophrenia risk variants and creativity. For NRG1 rs6994992, the result validated its association with creativity measures. However, since NRG1 rs6994992 is not a schizophrenia risk variant in the Han Chinese population, the validated association suggested that ethnic difference may exist in the relationship between NRG1 rs6994992, schizophrenia and creativity. For other schizophrenia risk variants, the result only demonstrated a nominal association between ZNF536 rs2053079 and creativity measures which would not survive correction for multiple testing. No association between polygenic risk score for these 10 schizophrenia risk variants and creativity measures was observed. In conclusion, this study provides limited evidence for the associations between these schizophrenia risk variants and creativity in healthy Han Chinese subjects. Future studies are warranted to better understand the potential genetic link between schizophrenia and creativity.
Collapse
Affiliation(s)
- Dan Wang
- Beijing Key Laboratory of Learning and Cognition, Department of Psychology, The Collaborative Innovation Center for Capital Education Development, Capital Normal University, Beijing, China
| | - Tingting Guo
- Beijing Gese Technology Co., Ltd., Beijing, China
| | - Qi Guo
- Beijing Key Laboratory of Learning and Cognition, Department of Psychology, The Collaborative Innovation Center for Capital Education Development, Capital Normal University, Beijing, China
| | - Shun Zhang
- Department of Psychology, Shandong Normal University, Jinan, China
| | - Jinghuan Zhang
- Department of Psychology, Shandong Normal University, Jinan, China
| | - Jing Luo
- Beijing Key Laboratory of Learning and Cognition, Department of Psychology, The Collaborative Innovation Center for Capital Education Development, Capital Normal University, Beijing, China
| | | |
Collapse
|
11
|
Lubis BM, Effendi SH, Ganie RA, Ramayani OR. Impact of the Neuregulin rs35753505 C/T Polymorphisms on Neuregulin 1 Levels in Preterm Infants. Open Access Maced J Med Sci 2019; 7:1931-1934. [PMID: 31406531 PMCID: PMC6684418 DOI: 10.3889/oamjms.2019.554] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2019] [Revised: 06/19/2019] [Accepted: 06/20/2019] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND Neuregulin (NRG) 1 plays an important role in the development of various organ systems in human. Single nucleotide polymorphisms rs35753505 C/Tof the gene encoding NRG1 evident as allele C and T with genotypes of CT, CC, and TT are believed to have an impact on NRG1 levels. AIM To determine the impact of the NRGrs35753505 C/T polymorphisms on NRG1 levels in preterm infants. METHODS A cross-sectional study was conducted from February to December 2018, whereas 48 eligible preterm infants with a gestational age of 32- < 37 weeks were enrolled. An umbilical cord blood specimen was collected for determination of NRG1 levels with enzyme-linked immunosorbent assay (ELISA) and NRG1 polymorphisms with polymerase chain reaction (PCR). Statistical analysis was performed with 95%CI and P value of < 0.05 was considered statistically significant. RESULTS Median value of NRG1 levels (174.4 pg/ml) served as a cut off value. NRG 1 polymorphisms composed distribution of CC (31%), CT (42%), TT (27%) genotypes and distribution of C and T alleles were 52% and 48%. The median NRG1 levels in CC and CT genotypes were significantly lower compared to TT genotype (151.1 pg/ml vs 407.2 pg/ml, P = 0.005 and 159.1 pg/ml vs 407.2 pg/ml, P = 0.009). Subjects with C allele had significantly lower median NRG1 levels than T allele (151.1 pg/ml vs 407.2 pg/ml, P = 0.002). Subjects with CC and CT genotypes had higher risk to develop lower NRG1 levels compared to TT genotype (OR = 8.25, P = 0.016 and OR = 10.74, P = 0.005, respectively). CONCLUSION Allele C is associated with lower NRG1 levels. Preterm infants with CC and CT genotypes pose a higher risk to have lower NRG1 levels.
Collapse
Affiliation(s)
- Bugis Mardina Lubis
- Department of Child Health, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
| | - Sjarif Hidajat Effendi
- Department of Child Health, Faculty of Medicine, Universitas Padjajaran, Bandung, Indonesia
| | - Ratna Akbari Ganie
- Department of Clinical Pathology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
| | - Oke Rina Ramayani
- Department of Child Health, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
| |
Collapse
|
12
|
Discoidin domain receptor 1 gene variants are associated with decreased white matter fractional anisotropy and decreased processing speed in schizophrenia. J Psychiatr Res 2019; 110:74-82. [PMID: 30597424 DOI: 10.1016/j.jpsychires.2018.12.021] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Revised: 12/04/2018] [Accepted: 12/21/2018] [Indexed: 12/20/2022]
Abstract
DDR1 has been linked to schizophrenia (SZ) and myelination. Here, we tested whether DDR1 variants in people at risk for SZ influence white matter (WM) structural variations and cognitive processing speed (PS). First, following a case-control design (Study 1), SZ patients (N = 1193) and controls (N = 1839) were genotyped for rs1264323 and rs2267641 at DDR1, and the frequencies were compared. We replicated the association between DDR1 and SZ (rs1264323, adjusted P = 0.015). Carriers of the rs1264323AA combined with the rs2267641AC or CC genotype are at risk to develop SZ compared to the other genotype combinations. Second, SZ patients (Study 2, N = 194) underwent an evaluation of PS using the Trail Making Test (TMT) and DDR1 genotyping. To compare PS between DDR1 genotype groups, we conducted an analysis of covariance (including rs1264323 as a covariate) and found that SZ patients with the rs2267641CC genotype had decreased PS compared to patients with the AA and AC genotypes. Third, 54 patients (Study 3) from Study 2 were selected based on rs1264323 genotype to undergo reevaluation, including a DTI-MRI brain scan. To test for associations between PS, WM microstructure and DDR1 genotype, we first localized those WM regions where fractional anisotropy (FA) was correlated with PS and tested whether FA showed differences between the rs1264323 genotypes. SZ patients with the rs1264323AA genotype showed decreased FA in WM regions associated with decreased PS. We conclude that DDR1 variants may confer a risk of SZ through WM microstructural alterations leading to cognitive dysfunction.
Collapse
|
13
|
Bousman CA, Cropley V, Klauser P, Hess JL, Pereira A, Idrizi R, Bruggemann J, Mostaid MS, Lenroot R, Weickert TW, Glatt SJ, Everall IP, Sundram S, Zalesky A, Weickert CS, Pantelis C. Neuregulin-1 (NRG1) polymorphisms linked with psychosis transition are associated with enlarged lateral ventricles and white matter disruption in schizophrenia. Psychol Med 2018; 48:801-809. [PMID: 28826413 DOI: 10.1017/s0033291717002173] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Two single-nucleotide polymorphisms (SNPs) (rs4281084 and rs12155594) within the neuregulin-1 (NRG1) gene have been associated with psychosis transition. However, the neurobiological changes associated with these SNPs remain unclear. We aimed to determine what relationship these two SNPs have on lateral ventricular volume and white matter integrity, as abnormalities in these brain structures are some of the most consistent in schizophrenia. METHODS Structural (n = 370) and diffusion (n = 465) magnetic resonance imaging data were obtained from affected and unaffected individuals predominantly of European descent. The SNPs rs4281084, rs12155594, and their combined allelic load were examined for their effects on lateral ventricular volume, fractional anisotropy (FA) as well as axial (AD) and radial (RD) diffusivity. Additional exploratory analyses assessed NRG1 effects on gray matter volume, cortical thickness, and surface area throughout the brain. RESULTS Individuals with a schizophrenia age of onset ⩽25 and a combined allelic load ⩾3 NRG1 risk alleles had significantly larger right (up to 50%, p adj = 0.01) and left (up to 45%, p adj = 0.05) lateral ventricle volumes compared with those with allelic loads of less than three. Furthermore, carriers of three or more risk alleles, regardless of age of onset and case status, had significantly reduced FA and elevated RD but stable AD in the frontal cortex compared with those carrying fewer than three risk alleles. CONCLUSIONS Our findings build on a growing body of research supporting the functional importance of genetic variation within the NRG1 gene and complement previous findings implicating the rs4281084 and rs12155594 SNPs as markers for psychosis transition.
Collapse
Affiliation(s)
- C A Bousman
- Department of Psychiatry,Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health,Carlton South, VIC,Australia
| | - V Cropley
- Department of Psychiatry,Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health,Carlton South, VIC,Australia
| | - P Klauser
- Department of Psychiatry,Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health,Carlton South, VIC,Australia
| | - J L Hess
- Psychiatric Genetic Epidemiology & Neurobiology Laboratory (PsychGENe Lab), Departments of Psychiatry and Behavioral Sciences and Neuroscience and Physiology,SUNY Upstate Medical University,Syracuse, New York
| | - A Pereira
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne,Parkville, VIC,Australia
| | - R Idrizi
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne,Parkville, VIC,Australia
| | - J Bruggemann
- Schizophrenia Research Institute,Sydney,Australia
| | - M S Mostaid
- Department of Psychiatry,Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health,Carlton South, VIC,Australia
| | - R Lenroot
- Schizophrenia Research Institute,Sydney,Australia
| | - T W Weickert
- Schizophrenia Research Institute,Sydney,Australia
| | - S J Glatt
- Psychiatric Genetic Epidemiology & Neurobiology Laboratory (PsychGENe Lab), Departments of Psychiatry and Behavioral Sciences and Neuroscience and Physiology,SUNY Upstate Medical University,Syracuse, New York
| | - I P Everall
- Department of Psychiatry,Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health,Carlton South, VIC,Australia
| | - S Sundram
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne,Parkville, VIC,Australia
| | - A Zalesky
- Department of Psychiatry,Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health,Carlton South, VIC,Australia
| | - C S Weickert
- Schizophrenia Research Institute,Sydney,Australia
| | - C Pantelis
- Department of Psychiatry,Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health,Carlton South, VIC,Australia
| |
Collapse
|
14
|
Rae CL, Davies G, Garfinkel SN, Gabel MC, Dowell NG, Cercignani M, Seth AK, Greenwood KE, Medford N, Critchley HD. Deficits in Neurite Density Underlie White Matter Structure Abnormalities in First-Episode Psychosis. Biol Psychiatry 2017; 82:716-725. [PMID: 28359565 DOI: 10.1016/j.biopsych.2017.02.008] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/03/2016] [Revised: 01/30/2017] [Accepted: 02/08/2017] [Indexed: 10/20/2022]
Abstract
BACKGROUND Structural abnormalities across multiple white matter tracts are recognized in people with early psychosis, consistent with dysconnectivity as a neuropathological account of symptom expression. We applied advanced neuroimaging techniques to characterize microstructural white matter abnormalities for a deeper understanding of the developmental etiology of psychosis. METHODS Thirty-five first-episode psychosis patients, and 19 healthy controls, participated in a quantitative neuroimaging study using neurite orientation dispersion and density imaging, a multishell diffusion-weighted magnetic resonance imaging technique that distinguishes white matter fiber arrangement and geometry from changes in neurite density. Fractional anisotropy (FA) and mean diffusivity images were also derived. Tract-based spatial statistics compared white matter structure between patients and control subjects and tested associations with age, symptom severity, and medication. RESULTS Patients with first-episode psychosis had lower regional FA in multiple commissural, corticospinal, and association tracts. These abnormalities predominantly colocalized with regions of reduced neurite density, rather than aberrant fiber bundle arrangement (orientation dispersion index). There was no direct relationship with active symptoms. FA decreased and orientation dispersion index increased with age in patients, but not control subjects, suggesting accelerated effects of white matter geometry change. CONCLUSIONS Deficits in neurite density appear fundamental to abnormalities in white matter integrity in early psychosis. In the first application of neurite orientation dispersion and density imaging in psychosis, we found that processes compromising axonal fiber number, density, and myelination, rather than processes leading to spatial disruption of fiber organization, are implicated in the etiology of psychosis. This accords with a neurodevelopmental origin of aberrant brain-wide structural connectivity predisposing individuals to psychosis.
Collapse
Affiliation(s)
- Charlotte L Rae
- Sackler Centre for Consciousness Science, University of Sussex, Falmer, Brighton; Division of Neuroscience, University of Sussex, Falmer, Brighton.
| | - Geoff Davies
- Brighton & Sussex Medical School, School of Psychology, University of Sussex, Falmer, Brighton; Sussex Partnership National Health Service Foundation Trust, United Kingdom
| | - Sarah N Garfinkel
- Sackler Centre for Consciousness Science, University of Sussex, Falmer, Brighton; Division of Neuroscience, University of Sussex, Falmer, Brighton
| | - Matt C Gabel
- Division of Neuroscience, University of Sussex, Falmer, Brighton
| | | | - Mara Cercignani
- Division of Neuroscience, University of Sussex, Falmer, Brighton
| | - Anil K Seth
- Sackler Centre for Consciousness Science, University of Sussex, Falmer, Brighton; School of Engineering & Informatics, University of Sussex, Falmer, Brighton
| | - Kathryn E Greenwood
- Brighton & Sussex Medical School, School of Psychology, University of Sussex, Falmer, Brighton; Sussex Partnership National Health Service Foundation Trust, United Kingdom
| | - Nick Medford
- Sackler Centre for Consciousness Science, University of Sussex, Falmer, Brighton; Division of Neuroscience, University of Sussex, Falmer, Brighton; Sussex Partnership National Health Service Foundation Trust, United Kingdom
| | - Hugo D Critchley
- Sackler Centre for Consciousness Science, University of Sussex, Falmer, Brighton; Division of Neuroscience, University of Sussex, Falmer, Brighton; Sussex Partnership National Health Service Foundation Trust, United Kingdom
| |
Collapse
|
15
|
Zhang Z, Huang J, Shen Y, Li R. BACE1-Dependent Neuregulin-1 Signaling: An Implication for Schizophrenia. Front Mol Neurosci 2017; 10:302. [PMID: 28993723 PMCID: PMC5622153 DOI: 10.3389/fnmol.2017.00302] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Accepted: 09/07/2017] [Indexed: 12/13/2022] Open
Abstract
Schizophrenia is a chronic psychiatric disorder with a lifetime prevalence of about 1% in the general population. Recent studies have shown that Neuregulin-1 (Nrg1) is a candidate gene for schizophrenia. At least 15 alternative splicing of NRG1 isoforms all contain an extracellular epidermal growth factor (EGF)-like domain, which is sufficient for Nrg1 biological activity including the formation of myelin sheaths and the regulation of synaptic plasticity. It is known that Nrg1 can be cleaved by β-secretase (BACE1) and the resulting N-terminal fragment (Nrg1-ntf) binds to receptor tyrosine kinase ErbB4, which activates Nrg1/ErbB4 signaling. While changes in Nrg1 expression levels in schizophrenia still remain controversial, understanding the BACE1-cleaved Nrg1-ntf and Nrg1/ErbB4 signaling in schizophrenia neuropathogenesis is essential and important. In this review paper, we included three major parts: (1) Nrg1 structure and cleavage pattern by BACE1; (2) BACE1-dependent Nrg1 cleavage associated with schizophrenia in human studies; and (3) Animal studies of Nrg1 and BACE1 mutations with behavioral observations. Our review will provide a better understanding of Nrg1 in schizophrenia and a potential strategy for using BACE1 cleavage of Nrg1 as a unique biomarker for diagnosis, as well as a new therapeutic target, of schizophrenia.
Collapse
Affiliation(s)
- Zhengrong Zhang
- National Clinical Research Center for Mental Disorders, Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical UniversityBeijing, China
| | - Jing Huang
- National Clinical Research Center for Mental Disorders, Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical UniversityBeijing, China
| | - Yong Shen
- Neurodegenerative Disorder Research Center, School of Life Sciences, University of Science and Technology of ChinaHefei, China.,Center for Therapeutic Strategies for Brain Disorders, Roskamp Institute, SarasotaFL, United States.,Center for Hormone Advanced Science and Education, Roskamp Institute, SarasotaFL, United States
| | - Rena Li
- National Clinical Research Center for Mental Disorders, Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical UniversityBeijing, China.,Center for Therapeutic Strategies for Brain Disorders, Roskamp Institute, SarasotaFL, United States.,Center for Hormone Advanced Science and Education, Roskamp Institute, SarasotaFL, United States.,Beijing Institute for Brain Disorders, Capital Medical UniversityBeijing, China
| |
Collapse
|
16
|
Romme IAC, de Reus MA, Ophoff RA, Kahn RS, van den Heuvel MP. Connectome Disconnectivity and Cortical Gene Expression in Patients With Schizophrenia. Biol Psychiatry 2017; 81:495-502. [PMID: 27720199 DOI: 10.1016/j.biopsych.2016.07.012] [Citation(s) in RCA: 136] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Revised: 07/16/2016] [Accepted: 07/18/2016] [Indexed: 12/13/2022]
Abstract
BACKGROUND Genome-wide association studies have identified several common risk loci for schizophrenia (SCZ). In parallel, neuroimaging studies have shown consistent findings of widespread white matter disconnectivity in patients with SCZ. METHODS We examined the role of genes in brain connectivity in patients with SCZ by combining transcriptional profiles of 43 SCZ risk genes identified by the recent genome-wide association study of the Schizophrenia Working Group of the Psychiatric Genomics Consortium with data on macroscale connectivity reductions in patients with SCZ. Expression profiles of 43 Psychiatric Genomics Consortium SCZ risk genes were extracted from the Allen Human Brain Atlas, and their average profile across the cortex was correlated to the pattern of cortical disconnectivity as derived from diffusion-weighted magnetic resonance imaging data of patients with SCZ (n = 48) and matched healthy controls (n = 43). RESULTS The expression profile of SCZ risk genes across cortical regions was significantly correlated with the regional macroscale disconnectivity (r = .588; p = .017). In addition, effects were found to be potentially specific to SCZ, with transcriptional profiles not related to cortical disconnectivity in patients with bipolar I disorder (diffusion-weighted magnetic resonance imaging data; 216 patients, 144 controls). Further examination of correlations across all 20,737 genes present in the Allen Human Brain Atlas showed the set of top 100 strongest correlating genes to display significant enrichment for the disorder, potentially identifying new genes involved in the pathophysiology of SCZ. CONCLUSIONS Our results suggest that under disease conditions, cortical areas with pronounced expression of risk genes implicated in SCZ form central areas for white matter disconnectivity.
Collapse
Affiliation(s)
- Ingrid A C Romme
- Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Marcel A de Reus
- Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Roel A Ophoff
- Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands; Center for Neurobehavioral Genetics and Department of Human Genetics , University of California Los Angeles, Los Angeles, California
| | - René S Kahn
- Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Martijn P van den Heuvel
- Brain Center Rudolf Magnus, Department of Psychiatry, University Medical Center Utrecht, Utrecht, The Netherlands.
| |
Collapse
|
17
|
Variation at NRG1 genotype related to modulation of small-world properties of the functional cortical network. Eur Arch Psychiatry Clin Neurosci 2017; 267:25-32. [PMID: 26650688 DOI: 10.1007/s00406-015-0659-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/08/2015] [Accepted: 11/17/2015] [Indexed: 01/11/2023]
Abstract
Functional brain networks possess significant small-world (SW) properties. Genetic variation relevant to both inhibitory and excitatory transmission may contribute to modulate these properties. In healthy controls, genotypic variation in Neuregulin 1 (NRG1) related to the risk of psychosis (risk alleles) would contribute to functional SW modulation of the cortical network. Electroencephalographic activity during an odd-ball task was recorded in 144 healthy controls. Then, small-worldness (SWn) was calculated in five frequency bands (i.e., theta, alpha, beta1, beta2 and gamma) for baseline (from -300 to the stimulus onset) and response (150-450 ms post-target stimulus) windows. The SWn modulation was defined as the difference in SWn between both windows. Association between SWn modulation and carrying the risk allele for three single nucleotide polymorphisms (SNP) of NRG1 (i.e., rs6468119, rs6994992 and rs7005606) was assessed. A significant association between three SNPs of NRG1 and the SWn modulation was found, specifically: NRG1 rs6468119 in alpha and beta1 bands; NRG1 rs6994992 in theta band; and NRG1 rs7005606 in theta and beta1 bands. Genetic variation at NRG1 may influence functional brain connectivity through the modulation of SWn properties of the cortical network.
Collapse
|
18
|
Vaht M, Laas K, Kiive E, Parik J, Veidebaum T, Harro J. A functional neuregulin-1 gene variant and stressful life events: Effect on drug use in a longitudinal population-representative cohort study. J Psychopharmacol 2017; 31:54-61. [PMID: 27353026 DOI: 10.1177/0269881116655979] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
BACKGROUND The neuregulin 1 gene is a susceptibility gene for substance dependence. A functional polymorphism (SNP8NRG243177/rs6994992; C/T) in the promoter region of the brain-specific type IV neuregulin-1 gene ( NRG1) has been associated with psychiatric disorders (e.g. schizophrenia and bipolar disorder) that often present higher odds of smoking, alcohol and illicit drug use. This study assessed the association of the NRG1 genotype with drug use and possible interaction with stressful life events (SLEs). METHODS The database of the Estonian Children Personality Behaviour and Health Study (beginning in 1998) was used. Cohorts of children initially 9 years old ( n=583; followed up at 15 and 18 years) and 15 years old ( n=593; followed up at 18 and 25 years) provided self-reports on alcohol, tobacco and illicit substance use and SLEs. Psychiatric assessment based on DSM-IV was carried out on the older birth cohort at age 25 to assess the lifetime presence of substance use disorders. NRG1 rs6994992 was genotyped in all participants by TaqMan® Pre-Designed SNP Genotyping Assay on the Applied Biosystems ViiA™ 7 Real-Time PCR System. The minor (T) allele frequency was 0.37. RESULTS NRG1 rs6994992 C/C homozygotes, especially those who had experienced more SLEs, were more likely to develop alcohol use disorders by young adulthood, were generally more active consumers of tobacco products, and had more likely used illicit drugs. In T allele carriers, SLEs had a negligible effect on substance use. CONCLUSIONS In humans, NRG1 genotype is associated with substance use, and this relationship is moderated by adverse life events, with a gain-of-function allele being protective.
Collapse
Affiliation(s)
- Mariliis Vaht
- 1 Division of Neuropsychopharmacology, Department of Psychology, Estonian Centre of Behavioural and Health Sciences, University of Tartu, Tartu, Estonia
| | - Kariina Laas
- 1 Division of Neuropsychopharmacology, Department of Psychology, Estonian Centre of Behavioural and Health Sciences, University of Tartu, Tartu, Estonia
| | - Evelyn Kiive
- 2 Division of Special Education, Department of Education, University of Tartu, Tartu, Estonia
| | - Jüri Parik
- 3 Department of Molecular and Cell Biology, University of Tartu, Tartu, Estonia
| | - Toomas Veidebaum
- 4 National Institute for Health Development, Estonian Centre of Behavioural and Health Sciences, Tallinn, Estonia
| | - Jaanus Harro
- 1 Division of Neuropsychopharmacology, Department of Psychology, Estonian Centre of Behavioural and Health Sciences, University of Tartu, Tartu, Estonia
| |
Collapse
|
19
|
Sarıçiçek A, Zorlu N, Yalın N, Hıdıroğlu C, Çavuşoğlu B, Ceylan D, Ada E, Tunca Z, Özerdem A. Abnormal white matter integrity as a structural endophenotype for bipolar disorder. Psychol Med 2016; 46:1547-1558. [PMID: 26947335 DOI: 10.1017/s0033291716000180] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Several lines of evidence suggest that bipolar disorder (BD) is associated with white matter (WM) pathology. Investigation of unaffected first-degree relatives of BD patients may help to distinguish structural biomarkers of genetic risk without the confounding effects of burden of illness, medication or clinical state. In the present study, we applied tract-based spatial statistics to study WM changes in patients with BD, unaffected siblings and controls. METHOD A total of 27 euthymic patients with BD type I, 20 unaffected siblings of bipolar patients and 29 healthy controls who did not have any current or past diagnosis of Axis I psychiatric disorders were enrolled in the study. RESULTS Fractional anisotropy (FA) was significantly lower in BD patients than in the control group in the corpus callosum, fornix, bilateral superior longitudinal fasciculus, inferior longitudinal fasciculus, inferior fronto-occipital fasciculus, anterior thalamic radiation, posterior thalamic radiation, cingulum, uncinate fasciculus, superior corona radiata, anterior corona radiata and left external capsule. In region-of-interest (ROI) analyses, we found that both unaffected siblings and bipolar patients had significantly reduced FA in the left posterior thalamic radiation, the left sagittal stratum, and the fornix compared with healthy controls. Average FA for unaffected siblings was intermediate between the healthy controls and bipolar patients within these ROIs. CONCLUSIONS Decreased FA in the fornix, left posterior thalamic radiation and left sagittal stratum in both bipolar patients and unaffected siblings may represent a potential structural endophenotype or a trait-based marker for BD.
Collapse
Affiliation(s)
- A Sarıçiçek
- Department of Psychiatry,Faculty of Medicine,Izmir Katip Celebi University,Ataturk Training and Research Hospital,Izmir,Turkey
| | - N Zorlu
- Department of Psychiatry,Faculty of Medicine,Izmir Katip Celebi University,Ataturk Training and Research Hospital,Izmir,Turkey
| | - N Yalın
- Department of Neuroscience,Health Sciences Institute,Dokuz Eylul University,Izmir,Turkey
| | - C Hıdıroğlu
- Department of Neuroscience,Health Sciences Institute,Dokuz Eylul University,Izmir,Turkey
| | - B Çavuşoğlu
- Department of Neuroscience,Health Sciences Institute,Dokuz Eylul University,Izmir,Turkey
| | - D Ceylan
- Department of Neuroscience,Health Sciences Institute,Dokuz Eylul University,Izmir,Turkey
| | - E Ada
- Department of Radiology,Faculty of Medicine,Dokuz Eylul University,Izmir,Turkey
| | - Z Tunca
- Department of Neuroscience,Health Sciences Institute,Dokuz Eylul University,Izmir,Turkey
| | - A Özerdem
- Department of Neuroscience,Health Sciences Institute,Dokuz Eylul University,Izmir,Turkey
| |
Collapse
|
20
|
Kato T, Abe Y, Hirokawa S, Iwakura Y, Mizuno M, Namba H, Nawa H. Neurobehavioral Differences Between Mice Receiving Distinct Neuregulin Variants as Neonates; Impact on Sensitivity to MK-801. Curr Mol Med 2016; 15:222-36. [PMID: 25817857 PMCID: PMC4475761 DOI: 10.2174/1566524015666150330143300] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2014] [Revised: 02/20/2015] [Accepted: 03/25/2015] [Indexed: 12/29/2022]
Abstract
Neuregulin-1 (NRG1) is a well-recognized risk gene for schizophrenia and is often implicated in the neurodevelopmental hypothesis of this illness. Alternative splicing and proteolytic processing of the NRG1 gene produce more than 30 structural variants; however, the neuropathological roles of individual variants remain to be characterized. On the basis of the neurodevelopmental hypothesis of schizophrenia, we administered eNRG1 (0.1~1.0 μg/g), a core epidermal growth factor-like (EGF) domain common for all splicing NRG1 variants, to neonatal mice and compared their behavioral performance with mice challenged with a full mature form of type 1 NRG1 variant. During the neonatal stage, recombinant eNRG1 protein administrated from the periphery passed the blood-brain barrier and activated its receptor (ErbB4) in the brain. In adults, the mice receiving the highest dose exhibited lower locomotor activity and deficits in prepulse inhibition and tonedependent fear learning, although the hearing reduction of the eNRG1-treated mice may explain these behavioral deficits. Neonatal eNRG1 treatment also significantly potentiated MK-801-driven locomotor activity in an eNRG1 dose-dependent manner. In parallel eNRG1 treatment enhanced MK-801-driven c-Fos induction and decreased immunoreactivity for NMDA receptor subunits in adult brain. In contrast, mice that had been treated with the same molar dose of a full mature form of type 1 NRG1 as neonates did not exhibit hypersensitivity to MK-801. However, both animal models exhibited similar hypersensitivity to methamphetamine. Collectively, our findings suggest that aberrant peripheral NRG1 signals during neurodevelopment alter later behavioral traits and auditory functions in the NRG1 subtype-dependent manner.
Collapse
Affiliation(s)
| | | | | | | | | | | | - H Nawa
- Department of Molecular Neurobiology, Brain Research Institute, Niigata University, 1-757 Asahimachi-dori, Niigata 951-8585, Japan.
| |
Collapse
|
21
|
Landek-Salgado MA, Faust TE, Sawa A. Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Mol Psychiatry 2016; 21:10-28. [PMID: 26390828 PMCID: PMC4684728 DOI: 10.1038/mp.2015.141] [Citation(s) in RCA: 74] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2014] [Revised: 06/24/2015] [Accepted: 06/25/2015] [Indexed: 02/06/2023]
Abstract
Schizophrenia (SZ) is a devastating psychiatric condition affecting numerous brain systems. Recent studies have identified genetic factors that confer an increased risk of SZ and participate in the disease etiopathogenesis. In parallel to such bottom-up approaches, other studies have extensively reported biological changes in patients by brain imaging, neurochemical and pharmacological approaches. This review highlights the molecular substrates identified through studies with SZ patients, namely those using top-down approaches, while also referring to the fruitful outcomes of recent genetic studies. We have subclassified the molecular substrates by system, focusing on elements of neurotransmission, targets in white matter-associated connectivity, immune/inflammatory and oxidative stress-related substrates, and molecules in endocrine and metabolic cascades. We further touch on cross-talk among these systems and comment on the utility of animal models in charting the developmental progression and interaction of these substrates. Based on this comprehensive information, we propose a framework for SZ research based on the hypothesis of an imbalance in homeostatic signaling from immune/inflammatory, oxidative stress, endocrine and metabolic cascades that, at least in part, underlies deficits in neural connectivity relevant to SZ. Thus, this review aims to provide information that is translationally useful and complementary to pathogenic hypotheses that have emerged from genetic studies. Based on such advances in SZ research, it is highly expected that we will discover biomarkers that may help in the early intervention, diagnosis or treatment of SZ.
Collapse
Affiliation(s)
- M A Landek-Salgado
- Department of Psychiatry, John Hopkins University School of Medicine, Baltimore, MD, USA
| | - T E Faust
- Department of Psychiatry, John Hopkins University School of Medicine, Baltimore, MD, USA.,Department of Neuroscience, John Hopkins University School of Medicine, Baltimore, MD, USA
| | - A Sawa
- Department of Psychiatry, John Hopkins University School of Medicine, Baltimore, MD, USA
| |
Collapse
|
22
|
Monin A, Fournier M, Baumann PS, Cuénod M, Do KQ. Role of Redox Dysregulation in White Matter Anomalies Associated with Schizophrenia. HANDBOOK OF BEHAVIORAL NEUROSCIENCE 2016. [DOI: 10.1016/b978-0-12-800981-9.00028-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
23
|
Budisavljevic S, Kawadler JM, Dell'Acqua F, Rijsdijk FV, Kane F, Picchioni M, McGuire P, Toulopoulou T, Georgiades A, Kalidindi S, Kravariti E, Murray RM, Murphy DG, Craig MC, Catani M. Heritability of the limbic networks. Soc Cogn Affect Neurosci 2015; 11:746-57. [PMID: 26714573 PMCID: PMC4847695 DOI: 10.1093/scan/nsv156] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2015] [Accepted: 12/16/2015] [Indexed: 11/18/2022] Open
Abstract
Individual differences in cognitive ability and social behaviour are influenced by the variability in the structure and function of the limbic system. A strong heritability of the limbic cortex has been previously reported, but little is known about how genetic factors influence specific limbic networks. We used diffusion tensor imaging tractography to investigate heritability of different limbic tracts in 52 monozygotic and 34 dizygotic healthy adult twins. We explored the connections that contribute to the activity of three distinct functional limbic networks, namely the dorsal cingulum (‘medial default-mode network’), the ventral cingulum and the fornix (‘hippocampal-diencephalic-retrosplenial network’) and the uncinate fasciculus (‘temporo-amygdala-orbitofrontal network’). Genetic and environmental variances were mapped for multiple tract-specific measures that reflect different aspects of the underlying anatomy. We report the highest heritability for the uncinate fasciculus, a tract that underpins emotion processing, semantic cognition, and social behaviour. High to moderate genetic and shared environmental effects were found for pathways important for social behaviour and memory, for example, fornix, dorsal and ventral cingulum. These findings indicate that within the limbic system inheritance of specific traits may rely on the anatomy of distinct networks and is higher for fronto-temporal pathways dedicated to complex social behaviour and emotional processing.
Collapse
Affiliation(s)
- Sanja Budisavljevic
- Department of Forensic and Neurodevelopmental Sciences, and Natbrainlab, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK, NEMo Laboratory, Department of General Psychology, University of Padova, 35131 Padova, Italy,
| | - Jamie M Kawadler
- Department of Forensic and Neurodevelopmental Sciences, and Natbrainlab, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK
| | - Flavio Dell'Acqua
- Department of Forensic and Neurodevelopmental Sciences, and Natbrainlab, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK
| | | | | | | | | | - Timothea Toulopoulou
- Department of Psychological Medicine, and Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK, Department of Psychology, and State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong, Hong Kong, and
| | - Anna Georgiades
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK
| | - Sridevi Kalidindi
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK
| | - Eugenia Kravariti
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK
| | - Robin M Murray
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK
| | | | - Michael C Craig
- Department of Forensic and Neurodevelopmental Sciences, and Natbrainlab, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK, National Autism Unit, South London and Maudsley NHS Foundation Trust, Beckenham, UK
| | - Marco Catani
- Department of Forensic and Neurodevelopmental Sciences, and Natbrainlab, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK
| |
Collapse
|
24
|
Wang C, Aleksic B, Ozaki N. Glia-related genes and their contribution to schizophrenia. Psychiatry Clin Neurosci 2015; 69:448-61. [PMID: 25759284 DOI: 10.1111/pcn.12290] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/08/2015] [Indexed: 12/24/2022]
Abstract
Schizophrenia, a debilitating disease with 1% prevalence in the general population, is characterized by major neuropsychiatric symptoms, including delusions, hallucinations, and deficits in emotional and social behavior. Previous studies have directed their investigations on the mechanism of schizophrenia towards neuronal dysfunction and have defined schizophrenia as a 'neuron-centric' disorder. However, along with the development of genetics and systematic biology approaches in recent years, the crucial role of glial cells in the brain has also been shown to contribute to the etiopathology of schizophrenia. Here, we summarize comprehensive data that support the involvement of glial cells (including oligodendrocytes, astrocytes, and microglial cells) in schizophrenia and list several acknowledged glia-related genes or molecules associated with schizophrenia. Instead of purely an abnormality of neurons in schizophrenia, an additional 'glial perspective' provides us a novel and promising insight into the causal mechanisms and treatment for this disease.
Collapse
Affiliation(s)
- Chenyao Wang
- Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Branko Aleksic
- Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - Norio Ozaki
- Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
25
|
Deloulme JC, Gory-Fauré S, Mauconduit F, Chauvet S, Jonckheere J, Boulan B, Mire E, Xue J, Jany M, Maucler C, Deparis AA, Montigon O, Daoust A, Barbier EL, Bosc C, Deglon N, Brocard J, Denarier E, Le Brun I, Pernet-Gallay K, Vilgrain I, Robinson PJ, Lahrech H, Mann F, Andrieux A. Microtubule-associated protein 6 mediates neuronal connectivity through Semaphorin 3E-dependent signalling for axonal growth. Nat Commun 2015; 6:7246. [PMID: 26037503 PMCID: PMC4468860 DOI: 10.1038/ncomms8246] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2014] [Accepted: 04/22/2015] [Indexed: 01/07/2023] Open
Abstract
Structural microtubule associated proteins (MAPs) stabilize microtubules, a property that was thought to be essential for development, maintenance and function of neuronal circuits. However, deletion of the structural MAPs in mice does not lead to major neurodevelopment defects. Here we demonstrate a role for MAP6 in brain wiring that is independent of microtubule binding. We find that MAP6 deletion disrupts brain connectivity and is associated with a lack of post-commissural fornix fibres. MAP6 contributes to fornix development by regulating axonal elongation induced by Semaphorin 3E. We show that MAP6 acts downstream of receptor activation through a mechanism that requires a proline-rich domain distinct from its microtubule-stabilizing domains. We also show that MAP6 directly binds to SH3 domain proteins known to be involved in neurite extension and semaphorin function. We conclude that MAP6 is critical to interface guidance molecules with intracellular signalling effectors during the development of cerebral axon tracts. Loss of the structural microtubule-associated protein 6 (MAP6) leads to neuronal differentiation defects that are independent of MAP6's microtubule-binding properties. Here the authors establish a functional link between MAP6 and Semaphorin 3E signalling for proper formation of the fornix of the brain.
Collapse
Affiliation(s)
- Jean-Christophe Deloulme
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France
| | - Sylvie Gory-Fauré
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France
| | - Franck Mauconduit
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France
| | - Sophie Chauvet
- Aix-Marseille Université, CNRS, IBDM UMR 7288, 13288 Marseille, France
| | - Julie Jonckheere
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France
| | - Benoit Boulan
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France
| | - Erik Mire
- Aix-Marseille Université, CNRS, IBDM UMR 7288, 13288 Marseille, France
| | - Jing Xue
- Cell Signalling Unit, Children's Medical Research Institute, University of Sydney, Wentworthville, New South Wales 2145, Australia
| | - Marion Jany
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France
| | - Caroline Maucler
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France
| | - Agathe A Deparis
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France
| | - Olivier Montigon
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France [3] Centre Hospitalier Universitaire de Grenoble, IRMaGe, 38043 Grenoble, France [4] CNRS, UMS 3552, 38042 Grenoble, France
| | - Alexia Daoust
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France
| | - Emmanuel L Barbier
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France
| | - Christophe Bosc
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France
| | - Nicole Deglon
- 1] Lausanne University Hospital (CHUV), Department of Clinical Neurosciences (DNC), Laboratory of Cellular and Molecular Neurotherapies (LCMN), 1011 Lausanne, Switzerland [2] Lausanne University Hospital (CHUV), Neuroscience Research Center (CRN), 1011 Lausanne, Switzerland
| | - Jacques Brocard
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France
| | - Eric Denarier
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France [3] CEA, iRTSV, F-38000 Grenoble, France
| | - Isabelle Le Brun
- 1] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France [2] INSERM, U1036, 38054 Grenoble, France [3] CEA, iRTSV, F-38000 Grenoble, France
| | - Karin Pernet-Gallay
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France
| | - Isabelle Vilgrain
- 1] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France [2] INSERM, U1036, 38054 Grenoble, France [3] INSERM, U1036, 38054 Grenoble, France
| | - Phillip J Robinson
- Cell Signalling Unit, Children's Medical Research Institute, University of Sydney, Wentworthville, New South Wales 2145, Australia
| | - Hana Lahrech
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France [3] CEA, LETI, CLINATEC, MINATEC Campus, F-38054 Grenoble, France
| | - Fanny Mann
- Aix-Marseille Université, CNRS, IBDM UMR 7288, 13288 Marseille, France
| | - Annie Andrieux
- 1] INSERM, U836, F-38000 Grenoble, France [2] Univ. Grenoble Alpes, Grenoble Institut Neurosciences, F-38000 Grenoble, France [3] CEA, iRTSV, F-38000 Grenoble, France
| |
Collapse
|
26
|
Suárez-Pinilla P, Roíz-Santiañez R, Mata I, Ortiz-García de la Foz V, Brambilla P, Fañanas L, Valle-San Román N, Crespo-Facorro B. Progressive Structural Brain Changes and NRG1 Gene Variants in First-Episode Nonaffective Psychosis. Neuropsychobiology 2015; 71:103-111. [PMID: 25871612 DOI: 10.1159/000370075] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2014] [Accepted: 11/11/2014] [Indexed: 11/19/2022]
Abstract
BACKGROUND Structural brain abnormalities are already present during the early phases of psychosis, but factors underlying brain volume changes are still not well understood. The neuregulin 1 gene (NRG1), influencing neurodevelopment and neuroplasticity, has been associated with schizophrenia. Our aim was to examine whether variations in the NRG1 gene (SNP8NRG221132, SNP8NRG6221533 and SNP8NRG243177 polymorphisms) influence longitudinal changes in the brain during a first episode of psychosis (FEP). METHODS A 3-year follow-up magnetic resonance imaging (MRI) study was performed. Fifty-nine minimally medicated patients who were experiencing FEP and 14 healthy control individuals underwent genotyping and structural brain MRI at baseline and at 1- and 3-year follow-up. A comparison of brain volumes, gray matter, white matter (WM), lateral ventricles (LV), cortical cerebrospinal fluid, and thalamus and caudate was made between the groups according to their genotype. RESULTS In patients, the SNP8NRG6221533 risk C allele was significantly associated with increased LV volume across time. C allele carriers had significantly less WM compared with subjects homozygous for the T allele after the follow-up. No other significant differences were observed among subgroups. No significant changes according to the genotypes were found in healthy individuals. CONCLUSION Our findings suggest that variations of neurodevelopment-related genes, such as the NRG1 gene, can contribute to brain abnormalities described in early phases of schizophrenia and progressive changes during the initial years of the illness. To our knowledge, it is the first time that a relation between NRG1 polymorphisms and longitudinal brain changes is reported. © 2015 S. Karger AG, Basel.
Collapse
Affiliation(s)
- Paula Suárez-Pinilla
- Department of Psychiatry, University Hospital Marqués de Valdecilla, School of Medicine, University of Cantabria, Santander, Spain
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Two functional promoter polymorphisms of neuregulin 1 gene are associated with progressive forms of multiple sclerosis. J Neurol Sci 2015; 351:154-159. [DOI: 10.1016/j.jns.2015.03.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2014] [Revised: 02/06/2015] [Accepted: 03/04/2015] [Indexed: 01/19/2023]
|
28
|
Arat HE, Chouinard VA, Cohen BM, Lewandowski KE, Öngür D. Diffusion tensor imaging in first degree relatives of schizophrenia and bipolar disorder patients. Schizophr Res 2015; 161:329-39. [PMID: 25542860 PMCID: PMC4308443 DOI: 10.1016/j.schres.2014.12.008] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2014] [Revised: 12/03/2014] [Accepted: 12/05/2014] [Indexed: 11/29/2022]
Abstract
OBJECTIVES White matter (WM) abnormalities are one of the most widely and consistently reported findings in schizophrenia (SZ) and bipolar disorder (BD). If these abnormalities are inherited determinants of illness, suitable to be classified as an endophenotype, relatives of patients must also have them at higher rate compared to the general population. In this review, we evaluate published diffusion tensor imaging (DTI) studies comparing first degree relatives of SZ and BD patients and healthy control subjects. METHODS We searched PubMed, Embase and PsychInfo for DTI studies which included an unaffected relative and a healthy comparison group. RESULTS 22 studies fulfilled the inclusion criteria. WM abnormalities were found in many diverse regions in relatives of SZ patients. Although the findings were not completely consistent across studies, the most implicated areas were the frontal and temporal WM regions and the corpus callosum. Studies in relatives of BD patients were fewer in number with less consistent findings reported across studies. CONCLUSIONS Our review supports the concept of WM abnormalities as an endophenotype in SZ, with somewhat weaker evidence in BD, but larger and higher quality studies are needed to make a definitive comment.
Collapse
Affiliation(s)
- Hidayet E. Arat
- Dokuz Eylul University, Faculty of Medicine Department of Psychiatry, Izmir, Turkey,McLean Hospital, 115 Mill St., Belmont, MA, 02478 USA
| | - Virginie-Anne Chouinard
- McLean Hospital, 115 Mill St., Belmont, MA, 02478 USA,Harvard Medical School, Department of Psychiatry, Boston, MA, 02114 USA
| | - Bruce M. Cohen
- McLean Hospital, 115 Mill St., Belmont, MA, 02478 USA,Harvard Medical School, Department of Psychiatry, Boston, MA, 02114 USA
| | - Kathryn E. Lewandowski
- McLean Hospital, 115 Mill St., Belmont, MA, 02478 USA,Harvard Medical School, Department of Psychiatry, Boston, MA, 02114 USA
| | - Dost Öngür
- McLean Hospital, 115 Mill St., Belmont, MA 02478, USA; Harvard Medical School, Department of Psychiatry, Boston, MA 02114, USA.
| |
Collapse
|
29
|
Voineskos AN. Genetic underpinnings of white matter 'connectivity': heritability, risk, and heterogeneity in schizophrenia. Schizophr Res 2015; 161:50-60. [PMID: 24893906 DOI: 10.1016/j.schres.2014.03.034] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/23/2014] [Revised: 03/11/2014] [Accepted: 03/12/2014] [Indexed: 12/14/2022]
Abstract
Schizophrenia is a highly heritable disorder. Thus, the combination of genetics and brain imaging may be a useful strategy to investigate the effects of risk genes on anatomical connectivity, and for gene discovery, i.e. discovering the genetic correlates of white matter phenotypes. Following a database search, I review evidence for heritability of white matter phenotypes. I also review candidate gene investigations, examining association of putative risk variants with white matter phenotypes, as well as the recent flurry of research exploring relationships of genome-wide significant risk loci with white matter phenotypes. Finally, I review multivariate and polygene approaches, which constitute a new wave of imaging-genetics research, including large collaborative initiatives aiming to discover new genes that may predict aspects of white matter microstructure. The literature supports the heritability of white matter phenotypes. Loci in genes intimately implicated in oligodendrocyte and myelin development, growth and maintenance, and neurotrophic systems are associated with white matter microstructure. GWAS variants have not yet sufficiently been explored using DTI-based evaluation of white matter to draw conclusions, although micro-RNA 137 is promising due to its potential regulation of other GWAS schizophrenia genes. Many imaging-genetic studies only include healthy participants, which, while helping control for certain confounds, cannot address questions related to disease heterogeneity or symptom expression, and thus more studies should include participants with schizophrenia. With sufficiently large sample sizes, the future of this field lies in polygene strategies aimed at risk prediction and heterogeneity dissection of schizophrenia that can translate to personalized interventions.
Collapse
Affiliation(s)
- Aristotle N Voineskos
- Kimel Family Translational Imaging-Genetics Laboratory, Research Imaging Centre, Campbell Family Mental Health Institute, Centre for Addiction and Mental Health, Canada; Institute of Medical Science, University of Toronto, Canada; Department of Psychiatry, University of Toronto, Canada.
| |
Collapse
|
30
|
Peters BD, Karlsgodt KH. White matter development in the early stages of psychosis. Schizophr Res 2015; 161:61-9. [PMID: 24893908 PMCID: PMC4250450 DOI: 10.1016/j.schres.2014.05.021] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/21/2014] [Revised: 05/06/2014] [Accepted: 05/09/2014] [Indexed: 12/19/2022]
Abstract
Schizophrenia has been conceptualized as a disorder of both neurodevelopment and a disorder of connectivity. One important aspect of the neurodevelopmental hypothesis is that schizophrenia is no longer thought to have discrete illness time points, but rather a long trajectory of brain changes, spanning many years, across a series of stages of the disease including the prodrome, first episode, and chronic period. As the disease progresses, there is a complex relationship between age related changes and disease related changes. Therefore, neural changes, and specifically white matter based connectivity changes, in schizophrenia may be best conceptualized based on a lifespan trajectory. In this selective review, we discuss healthy changes in white matter integrity that occur with age, as well as changes that occur across illness stages. We further propose a set of models that might explain lifespan changes in white matter integrity in schizophrenia, with the conclusion that the evidence most strongly supports a pattern of disrupted maturation during adolescence, with the potential for later changes that may be a result of disease neurotoxicity, abnormal or excessive aging effects, as well as medication, cohort or other effects. Thus, when considering white matter integrity in psychosis, it is critical to consider age in addition to other contributing factors including disease specific effects. Discovery of the factors driving healthy white matter development across the lifespan and deviations from the normal developmental trajectory may provide insights relevant to the discovery of early treatment interventions.
Collapse
Affiliation(s)
- Bart D. Peters
- Division of Psychiatry Research, Zucker Hillside Hospital, NorthShore-LIJ Health System, Glen Oaks, NY
| | - Katherine H. Karlsgodt
- Division of Psychiatry Research, Zucker Hillside Hospital, NorthShore-LIJ Health System, Glen Oaks, NY,Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research, Manhasset, NY,Department of Psychiatry, Hofstra NorthShore-LIJ School of Medicine, Hempstead, NY
| |
Collapse
|
31
|
Mei L, Nave KA. Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases. Neuron 2014; 83:27-49. [PMID: 24991953 DOI: 10.1016/j.neuron.2014.06.007] [Citation(s) in RCA: 426] [Impact Index Per Article: 38.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Neuregulins (NRGs) comprise a large family of growth factors that stimulate ERBB receptor tyrosine kinases. NRGs and their receptors, ERBBs, have been identified as susceptibility genes for diseases such as schizophrenia (SZ) and bipolar disorder. Recent studies have revealed complex Nrg/Erbb signaling networks that regulate the assembly of neural circuitry, myelination, neurotransmission, and synaptic plasticity. Evidence indicates there is an optimal level of NRG/ERBB signaling in the brain and deviation from it impairs brain functions. NRGs/ERBBs and downstream signaling pathways may provide therapeutic targets for specific neuropsychiatric symptoms.
Collapse
Affiliation(s)
- Lin Mei
- Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA; Department of Neurology, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA; Charlie Norwood VA Medical Center, Augusta, GA 30904, USA.
| | - Klaus-Armin Nave
- Department of Neurogenetics, Max Planck Institute of Experimental Medicine, 37075 Goettingen, Germany.
| |
Collapse
|
32
|
Paterson C, Wang Y, Kleinman JE, Law AJ. Effects of schizophrenia risk variation in the NRG1 gene on NRG1-IV splicing during fetal and early postnatal human neocortical development. Am J Psychiatry 2014; 171:979-89. [PMID: 24935406 PMCID: PMC4330971 DOI: 10.1176/appi.ajp.2014.13111518] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
OBJECTIVE Neuregulin 1 (NRG1) is a multifunctional neurotrophin that mediates neurodevelopment and schizophrenia risk. The NRG1 gene undergoes extensive alternative splicing, and association of brain NRG1 type IV isoform expression with the schizophrenia-risk polymorphism rs6994992 is a potential mechanism of risk. Novel splice variants of NRG1-IV (NRG1-IVNV), with predicted unique signaling capabilities, have been cloned in fetal brain tissue. The authors investigated the temporal dynamics of transcription of NRG1-IVNV, compared with the major NRG1 isoforms, across human prenatal and postnatal prefrontal cortical development, and they examined the association of rs6994992 with NRG1-IVNV expression. METHOD NRG1 type I-IV and NRG1-IVNV isoforms were evaluated with quantitative real-time polymerase chain reaction in human postmortem prefrontal cortex tissue samples at 14 to 39 weeks gestation and postnatal ages 0-83 years. The association of rs6994992 genotype with NRG1-IVNV expression and the subcellular distribution and proteolytic processing of NRG1-IVNV isoforms were also determined. RESULTS Expression of NRG1 types I, II, and III was temporally regulated during prenatal and postnatal neocortical development. NRG1-IVNV was expressed from 16 weeks gestation until age 3. Homozygosity for the schizophrenia risk allele (T) of rs6994992 conferred lower cortical NRG1-IVNV levels. Assays showed that NRG1-IVNV is a novel nuclear-enriched, truncated NRG1 protein resistant to proteolytic processing. CONCLUSIONS To the authors' knowledge, this study provides the first quantitative map of NRG1 isoform expression during human neocortical development and aging. It identifies a potential mechanism of early developmental risk for schizophrenia at the NRG1 locus, involving a novel class of NRG1 proteins.
Collapse
Affiliation(s)
- Clare Paterson
- Department of Psychiatry, University of Colorado, School of Medicine, Aurora, CO 80045, USA,Clinical Brain Disorders Branch, Genes, Cognition and Psychosis Program, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1385, USA
| | - Yanhong Wang
- Clinical Brain Disorders Branch, Genes, Cognition and Psychosis Program, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1385, USA,Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, 855 N Wolfe Street, Baltimore, Maryland 21205
| | - Joel E. Kleinman
- Clinical Brain Disorders Branch, Genes, Cognition and Psychosis Program, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1385, USA,Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, 855 N Wolfe Street, Baltimore, Maryland 21205
| | - Amanda J. Law
- Department of Psychiatry, University of Colorado, School of Medicine, Aurora, CO 80045, USA,Clinical Brain Disorders Branch, Genes, Cognition and Psychosis Program, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1385, USA,Corresponding author:
| |
Collapse
|
33
|
Thirunavukkarasu P, Vijayakumari AA, John JP, Halahalli HN, Paul P, Sen S, Purushottam M, Jain S. An exploratory association study of the influence of dysbindin and neuregulin polymorphisms on brain morphometry in patients with schizophrenia and healthy subjects from South India. Asian J Psychiatr 2014; 10:62-8. [PMID: 25042954 DOI: 10.1016/j.ajp.2014.04.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Revised: 04/09/2014] [Accepted: 04/13/2014] [Indexed: 01/20/2023]
Abstract
Multiple genetic risk variants may act in a convergent manner leading on to the pathophysiological alterations of brain structure and function in schizophrenia. We examined the effect of polymorphisms of two candidate genes that mediate glutamatergic signaling, viz., dysbindin (rs1011313) and neuregulin (rs35753505), on brain morphometry in patients with schizophrenia (N=38) and healthy subjects (N=37) from South India. Patients with schizophrenia showed trend-level (p<0.001 uncorrected, 20 voxel extent correction) volumetric reductions in multiple brain regions when compared to healthy control subjects. Trend-level volumetric differences were also noted between homozygotes of the risk allele (AA) of the neuregulin (NRG1) polymorphism and heterozygotes (AG), as well as homozygotes of the risk allele (CC) of the dysbindin (DTNBP1) polymorphism and heterozygotes (TC), irrespective of diagnosis. Moreover, an additive effect of the risk alleles on brain morphometry was also noted. These preliminary findings highlight the possible influence of polymorphisms of risk genes on brain morphometry in schizophrenia.
Collapse
Affiliation(s)
- Priyadarshini Thirunavukkarasu
- Multimodal Brain Image Analysis Laboratory (MBIAL), NIMHANS, Bangalore 560029, India; Department of Psychiatry, NIMHANS, Bangalore 560029, India.
| | - Anupa A Vijayakumari
- Multimodal Brain Image Analysis Laboratory (MBIAL), NIMHANS, Bangalore 560029, India; Department of Psychiatry, NIMHANS, Bangalore 560029, India.
| | - John P John
- Multimodal Brain Image Analysis Laboratory (MBIAL), NIMHANS, Bangalore 560029, India; Department of Psychiatry, NIMHANS, Bangalore 560029, India; Department of Clinical Neuroscience, NIMHANS, Bangalore 560029, India.
| | - Harsha N Halahalli
- Multimodal Brain Image Analysis Laboratory (MBIAL), NIMHANS, Bangalore 560029, India; Department of Neurophysiology, NIMHANS, Bangalore 560029, India.
| | - Pradip Paul
- Department of Psychiatry, NIMHANS, Bangalore 560029, India; Molecular Genetics Laboratory, NIMHANS, Bangalore 560029, India.
| | - Somdatta Sen
- Department of Psychiatry, NIMHANS, Bangalore 560029, India; Molecular Genetics Laboratory, NIMHANS, Bangalore 560029, India.
| | - Meera Purushottam
- Department of Psychiatry, NIMHANS, Bangalore 560029, India; Molecular Genetics Laboratory, NIMHANS, Bangalore 560029, India.
| | - Sanjeev Jain
- Department of Psychiatry, NIMHANS, Bangalore 560029, India; Molecular Genetics Laboratory, NIMHANS, Bangalore 560029, India.
| |
Collapse
|
34
|
Savadjiev P, Rathi Y, Bouix S, Smith AR, Schultz RT, Verma R, Westin CF. Fusion of white and gray matter geometry: a framework for investigating brain development. Med Image Anal 2014; 18:1349-60. [PMID: 25066750 DOI: 10.1016/j.media.2014.06.013] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2014] [Revised: 06/05/2014] [Accepted: 06/30/2014] [Indexed: 01/11/2023]
Abstract
Current neuroimaging investigation of the white matter typically focuses on measurements derived from diffusion tensor imaging, such as fractional anisotropy (FA). In contrast, imaging studies of the gray matter oftentimes focus on morphological features such as cortical thickness, folding and surface curvature. As a result, it is not clear how to combine findings from these two types of approaches in order to obtain a consistent picture of morphological changes in both gray and white matter. In this paper, we propose a joint investigation of gray and white matter morphology by combining geometrical information from white and the gray matter. To achieve this, we first introduce a novel method for computing multi-scale white matter tract geometry. Its formulation is based on the differential geometry of curve sets and is easily incorporated into a continuous scale-space framework. We then incorporate this method into a novel framework for "fusing" white and gray matter geometrical information. Given a set of fiber tracts originating in a particular cortical region, the key idea is to compute two scalar fields that represent geometrical characteristics of the white matter and of the surface of the cortical region. A quantitative marker is created by combining the distributions of these scalar values using Mutual Information. This marker can be then used in the study of normal and pathological brain structure and development. We apply this framework to a study on autism spectrum disorder in children. Our preliminary results support the view that autism may be characterized by early brain overgrowth, followed by reduced or arrested growth (Courchesne, 2004).
Collapse
Affiliation(s)
- Peter Savadjiev
- Laboratory for Mathematics in Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
| | - Yogesh Rathi
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Sylvain Bouix
- Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Alex R Smith
- Section of Biomedical Image Analysis, Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
| | | | - Ragini Verma
- Section of Biomedical Image Analysis, Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
| | - Carl-Fredrik Westin
- Laboratory for Mathematics in Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
35
|
Brain white matter development is associated with a human-specific haplotype increasing the synthesis of long chain fatty acids. J Neurosci 2014; 34:6367-76. [PMID: 24790207 DOI: 10.1523/jneurosci.2818-13.2014] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The genetic and molecular pathways driving human brain white matter (WM) development are only beginning to be discovered. Long chain polyunsaturated fatty acids (LC-PUFAs) have been implicated in myelination in animal models and humans. The biosynthesis of LC-PUFAs is regulated by the fatty acid desaturase (FADS) genes, of which a human-specific haplotype is strongly associated with ω-3 and ω-6 LC-PUFA concentrations in blood. To investigate the relationship between LC-PUFA synthesis and human brain WM development, we examined whether this FADS haplotype is associated with age-related WM differences across the life span in healthy individuals 9-86 years of age (n = 207). Diffusion tensor imaging was performed to measure fractional anisotropy (FA), a putative measure of myelination, of the cerebral WM tracts. FADS haplotype status was determined with a single nucleotide polymorphism (rs174583) that tags this haplotype. Overall, normal age-related WM differences were observed, including higher FA values in early adulthood compared with childhood, followed by lower FA values across older age ranges. However, individuals homozygous for the minor allele (associated with lower LC-PUFA concentrations) did not display these normal age-related WM differences (significant age × genotype interactions, p(corrected) < 0.05). These findings suggest that LC-PUFAs are involved in human brain WM development from childhood into adulthood. This haplotype and LC-PUFAs may play a role in myelin-related disorders of neurodevelopmental origin.
Collapse
|
36
|
Thompson PM, Stein JL, Medland SE, Hibar DP, Vasquez AA, Renteria ME, Toro R, Jahanshad N, Schumann G, Franke B, Wright MJ, Martin NG, Agartz I, Alda M, Alhusaini S, Almasy L, Almeida J, Alpert K, Andreasen NC, Andreassen OA, Apostolova LG, Appel K, Armstrong NJ, Aribisala B, Bastin ME, Bauer M, Bearden CE, Bergmann Ø, Binder EB, Blangero J, Bockholt HJ, Bøen E, Bois C, Boomsma DI, Booth T, Bowman IJ, Bralten J, Brouwer RM, Brunner HG, Brohawn DG, Buckner RL, Buitelaar J, Bulayeva K, Bustillo JR, Calhoun VD, Cannon DM, Cantor RM, Carless MA, Caseras X, Cavalleri GL, Chakravarty MM, Chang KD, Ching CRK, Christoforou A, Cichon S, Clark VP, Conrod P, Coppola G, Crespo-Facorro B, Curran JE, Czisch M, Deary IJ, de Geus EJC, den Braber A, Delvecchio G, Depondt C, de Haan L, de Zubicaray GI, Dima D, Dimitrova R, Djurovic S, Dong H, Donohoe G, Duggirala R, Dyer TD, Ehrlich S, Ekman CJ, Elvsåshagen T, Emsell L, Erk S, Espeseth T, Fagerness J, Fears S, Fedko I, Fernández G, Fisher SE, Foroud T, Fox PT, Francks C, Frangou S, Frey EM, Frodl T, Frouin V, Garavan H, Giddaluru S, Glahn DC, Godlewska B, Goldstein RZ, Gollub RL, Grabe HJ, et alThompson PM, Stein JL, Medland SE, Hibar DP, Vasquez AA, Renteria ME, Toro R, Jahanshad N, Schumann G, Franke B, Wright MJ, Martin NG, Agartz I, Alda M, Alhusaini S, Almasy L, Almeida J, Alpert K, Andreasen NC, Andreassen OA, Apostolova LG, Appel K, Armstrong NJ, Aribisala B, Bastin ME, Bauer M, Bearden CE, Bergmann Ø, Binder EB, Blangero J, Bockholt HJ, Bøen E, Bois C, Boomsma DI, Booth T, Bowman IJ, Bralten J, Brouwer RM, Brunner HG, Brohawn DG, Buckner RL, Buitelaar J, Bulayeva K, Bustillo JR, Calhoun VD, Cannon DM, Cantor RM, Carless MA, Caseras X, Cavalleri GL, Chakravarty MM, Chang KD, Ching CRK, Christoforou A, Cichon S, Clark VP, Conrod P, Coppola G, Crespo-Facorro B, Curran JE, Czisch M, Deary IJ, de Geus EJC, den Braber A, Delvecchio G, Depondt C, de Haan L, de Zubicaray GI, Dima D, Dimitrova R, Djurovic S, Dong H, Donohoe G, Duggirala R, Dyer TD, Ehrlich S, Ekman CJ, Elvsåshagen T, Emsell L, Erk S, Espeseth T, Fagerness J, Fears S, Fedko I, Fernández G, Fisher SE, Foroud T, Fox PT, Francks C, Frangou S, Frey EM, Frodl T, Frouin V, Garavan H, Giddaluru S, Glahn DC, Godlewska B, Goldstein RZ, Gollub RL, Grabe HJ, Grimm O, Gruber O, Guadalupe T, Gur RE, Gur RC, Göring HHH, Hagenaars S, Hajek T, Hall GB, Hall J, Hardy J, Hartman CA, Hass J, Hatton SN, Haukvik UK, Hegenscheid K, Heinz A, Hickie IB, Ho BC, Hoehn D, Hoekstra PJ, Hollinshead M, Holmes AJ, Homuth G, Hoogman M, Hong LE, Hosten N, Hottenga JJ, Hulshoff Pol HE, Hwang KS, Jack CR, Jenkinson M, Johnston C, Jönsson EG, Kahn RS, Kasperaviciute D, Kelly S, Kim S, Kochunov P, Koenders L, Krämer B, Kwok JBJ, Lagopoulos J, Laje G, Landen M, Landman BA, Lauriello J, Lawrie SM, Lee PH, Le Hellard S, Lemaître H, Leonardo CD, Li CS, Liberg B, Liewald DC, Liu X, Lopez LM, Loth E, Lourdusamy A, Luciano M, Macciardi F, Machielsen MWJ, MacQueen GM, Malt UF, Mandl R, Manoach DS, Martinot JL, Matarin M, Mather KA, Mattheisen M, Mattingsdal M, Meyer-Lindenberg A, McDonald C, McIntosh AM, McMahon FJ, McMahon KL, Meisenzahl E, Melle I, Milaneschi Y, Mohnke S, Montgomery GW, Morris DW, Moses EK, Mueller BA, Muñoz Maniega S, Mühleisen TW, Müller-Myhsok B, Mwangi B, Nauck M, Nho K, Nichols TE, Nilsson LG, Nugent AC, Nyberg L, Olvera RL, Oosterlaan J, Ophoff RA, Pandolfo M, Papalampropoulou-Tsiridou M, Papmeyer M, Paus T, Pausova Z, Pearlson GD, Penninx BW, Peterson CP, Pfennig A, Phillips M, Pike GB, Poline JB, Potkin SG, Pütz B, Ramasamy A, Rasmussen J, Rietschel M, Rijpkema M, Risacher SL, Roffman JL, Roiz-Santiañez R, Romanczuk-Seiferth N, Rose EJ, Royle NA, Rujescu D, Ryten M, Sachdev PS, Salami A, Satterthwaite TD, Savitz J, Saykin AJ, Scanlon C, Schmaal L, Schnack HG, Schork AJ, Schulz SC, Schür R, Seidman L, Shen L, Shoemaker JM, Simmons A, Sisodiya SM, Smith C, Smoller JW, Soares JC, Sponheim SR, Sprooten E, Starr JM, Steen VM, Strakowski S, Strike L, Sussmann J, Sämann PG, Teumer A, Toga AW, Tordesillas-Gutierrez D, Trabzuni D, Trost S, Turner J, Van den Heuvel M, van der Wee NJ, van Eijk K, van Erp TGM, van Haren NEM, van ‘t Ent D, van Tol MJ, Valdés Hernández MC, Veltman DJ, Versace A, Völzke H, Walker R, Walter H, Wang L, Wardlaw JM, Weale ME, Weiner MW, Wen W, Westlye LT, Whalley HC, Whelan CD, White T, Winkler AM, Wittfeld K, Woldehawariat G, Wolf C, Zilles D, Zwiers MP, Thalamuthu A, Schofield PR, Freimer NB, Lawrence NS, Drevets W. The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav 2014; 8:153-82. [PMID: 24399358 PMCID: PMC4008818 DOI: 10.1007/s11682-013-9269-5] [Show More Authors] [Citation(s) in RCA: 530] [Impact Index Per Article: 48.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) Consortium is a collaborative network of researchers working together on a range of large-scale studies that integrate data from 70 institutions worldwide. Organized into Working Groups that tackle questions in neuroscience, genetics, and medicine, ENIGMA studies have analyzed neuroimaging data from over 12,826 subjects. In addition, data from 12,171 individuals were provided by the CHARGE consortium for replication of findings, in a total of 24,997 subjects. By meta-analyzing results from many sites, ENIGMA has detected factors that affect the brain that no individual site could detect on its own, and that require larger numbers of subjects than any individual neuroimaging study has currently collected. ENIGMA's first project was a genome-wide association study identifying common variants in the genome associated with hippocampal volume or intracranial volume. Continuing work is exploring genetic associations with subcortical volumes (ENIGMA2) and white matter microstructure (ENIGMA-DTI). Working groups also focus on understanding how schizophrenia, bipolar illness, major depression and attention deficit/hyperactivity disorder (ADHD) affect the brain. We review the current progress of the ENIGMA Consortium, along with challenges and unexpected discoveries made on the way.
Collapse
Affiliation(s)
- Paul M. Thompson
- Imaging Genetics Center, Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, 2001 N. Soto Street, Los Angeles, CA 90033 USA
| | - Jason L. Stein
- Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095 Netherlands
| | - Sarah E. Medland
- QIMR Berghofer Medical Research Institute, Quantitative Genetics, Brisbane, Australia
| | - Derrek P. Hibar
- Imaging Genetics Center, Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, 2001 N. Soto Street, Los Angeles, CA 90033 USA
| | - Alejandro Arias Vasquez
- Department of Human Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands
- Donders Institute for Brain, Cognition and Behaviour, Department of Cognitive Neuroscience, Radboud University Medical Centre, Nijmegen, The Netherlands
| | - Miguel E. Renteria
- QIMR Berghofer Medical Research Institute, Quantitative Genetics, Brisbane, Australia
| | - Roberto Toro
- Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France
- CNRS URA 2182 ‘Genes, synapses and cognition’, Institut Pasteur, Paris, France
- Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Université Paris Diderot, Paris, France
| | - Neda Jahanshad
- Imaging Genetics Center, Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, 2001 N. Soto Street, Los Angeles, CA 90033 USA
| | - Gunter Schumann
- MRC-SGDP Centre, Institute of Psychiatry, King’s College London, London, UK
| | - Barbara Franke
- Department of Human Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands
- Donders Institute for Brain, Cognition and Behaviour, Department of Cognitive Neuroscience, Radboud University Medical Centre, Nijmegen, The Netherlands
| | - Margaret J. Wright
- QIMR Berghofer Medical Research Institute, Neuroimaging Genetics, Brisbane, Australia
| | - Nicholas G. Martin
- QIMR Berghofer Medical Research Institute, Genetic Epidemiology, Brisbane, Australia
| | - Ingrid Agartz
- Department of Clinical Neuroscience, Karolinska Institutet and Hospital, Stockholm, Sweden
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Martin Alda
- Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia Canada
| | - Saud Alhusaini
- Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland
- Department of Neurology and NeuroSurgery, McGill University, Montreal, Quebec Canada
| | - Laura Almasy
- Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX USA
| | - Jorge Almeida
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA USA
- Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia Canada
| | - Kathryn Alpert
- Departments of Psychiatry and Behavioral Sciences and Radiology, Northwestern University, Chicago, IL USA
| | | | - Ole A. Andreassen
- NORMENT, KG Jebsen Centre for Psychosis Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Liana G. Apostolova
- Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA USA
| | - Katja Appel
- Department of Psychiatry and Psychotherapy, University of Greifswald, Greifswald, Germany
| | - Nicola J. Armstrong
- School of Mathematics and Statistics, University of Sydney, Sydney, Australia
| | - Benjamin Aribisala
- Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, 7 George Square, Edinburgh, UK
- Scottish Imaging Network, A Platform for Scientific Excellence (SINAPSE) Collaboration, Scotland, UK
- Brain Research Imaging Centre, The University of Edinburgh, Edinburgh, UK
| | - Mark E. Bastin
- Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, 7 George Square, Edinburgh, UK
- Brain Research Imaging Centre, The University of Edinburgh, Edinburgh, UK
- Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK
| | - Michael Bauer
- Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Dresden, Germany
| | - Carrie E. Bearden
- Department of Psychiatry and Biobehavioral Sciences and the Center for Neurobehavioral Genetics, The Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA USA
- Department of Psychology, UCLA, Los Angeles, CA USA
| | - Ørjan Bergmann
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | | | - John Blangero
- Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX USA
| | | | - Erlend Bøen
- Department of Psychosomatic Medicine, Oslo University Hospital, Oslo, Norway
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Catherine Bois
- Division of Psychiatry, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, UK
| | - Dorret I. Boomsma
- Department of Biological Psychology, VU University, Neuroscience Campus, Amsterdam, The Netherlands
- EMGO + Institute, VU University Medical Center, Amsterdam, The Netherlands
| | - Tom Booth
- Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, 7 George Square, Edinburgh, UK
| | - Ian J. Bowman
- Imaging Genetics Center, Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, 2001 N. Soto Street, Los Angeles, CA 90033 USA
| | - Janita Bralten
- Department of Human Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands
- Donders Institute for Brain, Cognition and Behaviour, Department of Cognitive Neuroscience, Radboud University Medical Centre, Nijmegen, The Netherlands
- Department of Cognitive Neuroscience, Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behavior, Nijmegen, The Netherlands
| | - Rachel M. Brouwer
- Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Han G. Brunner
- Department of Human Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands
| | - David G. Brohawn
- Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA USA
| | - Randy L. Buckner
- Massachusetts General Hospital, Boston, MA USA
- Center for Brain Science, Harvard University, Cambridge, MA USA
| | - Jan Buitelaar
- Donders Institute for Brain, Cognition and Behaviour, Department of Cognitive Neuroscience, Radboud University Medical Centre, Nijmegen, The Netherlands
- Karakter Child and Adolescent Psychiatry University Center, Nijmegen, The Netherlands
| | - Kazima Bulayeva
- N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences, Gubkin str. 3, Moscow, 119991 Russia
| | - Juan R. Bustillo
- Department of Psychiatry, University of New Mexico, Albuquerque, NM USA
| | - Vince D. Calhoun
- The Mind Research Network, Albuquerque, NM USA
- Department of Electrical and Computer Engineering, University of New Mexico, Albuquerque, NM USA
| | - Dara M. Cannon
- Clinical Neuroimaging Laboratory, National University of Ireland Galway, University Road, Galway, Ireland
| | - Rita M. Cantor
- Center for Neurobehavioral Genetics, University of California, Los Angeles, CA USA
| | - Melanie A. Carless
- Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX USA
| | - Xavier Caseras
- MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
| | - Gianpiero L. Cavalleri
- Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland
| | - M. Mallar Chakravarty
- The Kimel Family Translational Imaging Genetics Laboratory, The Centre for Addiction and Mental Health, Toronto, ON Canada
- Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON Canada
| | - Kiki D. Chang
- Department of Psychiatry, Stanford University School of Medicine, Stanford, CA USA
| | - Christopher R. K. Ching
- Imaging Genetics Center, Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, 2001 N. Soto Street, Los Angeles, CA 90033 USA
| | - Andrea Christoforou
- NORMENT, KG Jebsen Centre for Psychosis Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Dr Einar Martens Research Group for Biological Psychiatry, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Sven Cichon
- Institute of Human Genetics, University of Bonn, Bonn, Germany
- Institute for Neuroscience and Medicine (INM-1), Centre Jülich, Jülich, Germany
- Division of Medical Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland
| | - Vincent P. Clark
- Department of Psychology, University of New Mexico, Albuquerque, NM USA
| | - Patricia Conrod
- CHU Sainte Justine University Hospital Research Center, Montreal, QC Canada
- Addictions Department, King’s Health Partners, King’s College London, London, UK
| | - Giovanni Coppola
- Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA USA
- Department of Psychiatry and Biobehavioral Sciences and the Center for Neurobehavioral Genetics, The Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA USA
| | - Benedicto Crespo-Facorro
- Department of Psychiatry, Marqués de Valdecilla University Hospital, IFIMAV, School of Medicine, University of Cantabria, Santander, Spain
- Centro Investigación Biomédica en Red Salud Mental (CIBERSAM), Madrid, Spain
| | - Joanne E. Curran
- Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX USA
| | | | - Ian J. Deary
- Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, 7 George Square, Edinburgh, UK
| | - Eco J. C. de Geus
- Department of Biological Psychology, VU University, Neuroscience Campus, Amsterdam, The Netherlands
- EMGO + Institute, VU University Medical Center, Amsterdam, The Netherlands
| | - Anouk den Braber
- Department of Biological Psychology, VU University, Neuroscience Campus, Amsterdam, The Netherlands
| | | | - Chantal Depondt
- Department of Neurology, Hopital Erasme, Universite Libre de Bruxelles, 1070 Brussels, Belgium
| | - Lieuwe de Haan
- EMGO + Institute, VU University Medical Center, Amsterdam, The Netherlands
| | | | - Danai Dima
- MRC-SGDP Centre, Institute of Psychiatry, King’s College London, London, UK
| | - Rali Dimitrova
- Division of Psychiatry, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, UK
| | - Srdjan Djurovic
- NORMENT, KG Jebsen Centre for Psychosis Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
| | - Hongwei Dong
- Imaging Genetics Center, Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, 2001 N. Soto Street, Los Angeles, CA 90033 USA
| | - Gary Donohoe
- Clinical Neuroimaging Laboratory, National University of Ireland Galway, University Road, Galway, Ireland
- Neuropsychiatric Genetics Research Group, Department of Psychiatry, Institute for Molecular Medicine and Trinity College Institute for Neuroscience, Trinity College, Dublin, Ireland
| | | | - Thomas D. Dyer
- Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX USA
| | - Stefan Ehrlich
- MGH/HMS Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA USA
- University Hospital C.G. Carus, Department of Child and Adolescent Psychiatry, Dresden University of Technology, Dresden, Germany
| | - Carl Johan Ekman
- Department of Clinical Neuroscience, Karolinska Institutet and Hospital, Stockholm, Sweden
| | - Torbjørn Elvsåshagen
- Department of Psychosomatic Medicine, Oslo University Hospital, Oslo, Norway
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Louise Emsell
- Clinical Neuroimaging Laboratory, National University of Ireland Galway, University Road, Galway, Ireland
| | - Susanne Erk
- Department of Psychiatry and Psychotherapy, Charité, Universitaetsmedizin Berlin, Charitè Campus Mitte, Berlin, Germany
| | - Thomas Espeseth
- NORMENT, KG Jebsen Centre for Psychosis Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Department of Psychology, University of Oslo, Oslo, Norway
| | - Jesen Fagerness
- Massachusetts General Hospital, Boston, MA USA
- Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA USA
| | - Scott Fears
- Center for Neurobehavioral Genetics, University of California, Los Angeles, CA USA
- Department of Psychiatry and Biobehavioral Sciences and the Center for Neurobehavioral Genetics, The Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA USA
| | - Iryna Fedko
- Department of Biological Psychology, VU University, Neuroscience Campus, Amsterdam, The Netherlands
| | - Guillén Fernández
- Department of Cognitive Neuroscience, Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behavior, Nijmegen, The Netherlands
| | - Simon E. Fisher
- Donders Institute for Brain, Cognition and Behaviour, Department of Cognitive Neuroscience, Radboud University Medical Centre, Nijmegen, The Netherlands
- Max Planck Institute for Psycholinguistics, 6500 AH Nijmegen, The Netherlands
| | - Tatiana Foroud
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN USA
| | - Peter T. Fox
- Research Imaging Institute, UT Health Science Center at San Antonio, San Antonio, TX USA
- South Texas Veterans Health Care Center, San Antonio, TX USA
- South Texas Veterans Health Care System, San Antonio, TX USA
| | - Clyde Francks
- Donders Institute for Brain, Cognition and Behaviour, Department of Cognitive Neuroscience, Radboud University Medical Centre, Nijmegen, The Netherlands
- Max Planck Institute for Psycholinguistics, 6500 AH Nijmegen, The Netherlands
| | - Sophia Frangou
- Psychosis Research Unit, Mount Sinai School of Medicine, New York, NY USA
| | - Eva Maria Frey
- Department of Psychiatry and Psychotherapy, University Regensburg, Regensburg, Germany
| | - Thomas Frodl
- Department of Psychiatry and Psychotherapy, University Regensburg, Regensburg, Germany
- Department of Psychiatry and Psychotherapy, Trinity College, University Dublin, Dublin, Germany
| | - Vincent Frouin
- Neurospin, Commissariat à l’Energie Atomique, Paris, France
| | - Hugh Garavan
- Department of Psychiatry, UHC University of Vermont, Bergen, VT USA
| | - Sudheer Giddaluru
- Dr Einar Martens Research Group for Biological Psychiatry, Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
| | - David C. Glahn
- Olin Neuropsychiatry Research Center, Institute of Living, Hartford Hospital, Hartford, CT USA
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT USA
| | | | - Rita Z. Goldstein
- Department of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY USA
| | - Randy L. Gollub
- MGH/HMS Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA USA
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA USA
| | - Hans J. Grabe
- Department of Psychiatry and Psychotherapy, University of Greifswald, Greifswald, Germany
- German Center for Neurodegenerative Diseases (DZNE), University of Greifswald, Greifswald, Germany
- Department of Psychiatry and Psychotherapy, Helios Hospital Stralsund, Stralsund, Germany
| | - Oliver Grimm
- Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Oliver Gruber
- Center for Translational Research in Systems Neuroscience and Psychiatry, Department of Psychiatry, Georg August University, Goettingen, Germany
| | - Tulio Guadalupe
- Max Planck Institute for Psycholinguistics, 6500 AH Nijmegen, The Netherlands
| | - Raquel E. Gur
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA USA
| | - Ruben C. Gur
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA USA
- Philadelphia Veterans Administration Medical Center, Philadelphia, PA USA
| | - Harald H. H. Göring
- Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX USA
| | - Saskia Hagenaars
- Division of Psychiatry, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, UK
| | - Tomas Hajek
- Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia Canada
| | - Geoffrey B. Hall
- Department of Psychology, Neuroscience and Behaviour, McMaster University, Hamilton, ON Canada
| | - Jeremy Hall
- Division of Psychiatry, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, UK
- Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK
| | - John Hardy
- Department of Molecular Neuroscience, UCL Institute, London, UK
| | - Catharina A. Hartman
- Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Johanna Hass
- University Hospital C.G. Carus, Department of Child and Adolescent Psychiatry, Dresden University of Technology, Dresden, Germany
| | - Sean N. Hatton
- The Brain and Mind Research Institute, University of Sydney, Sydney, Australia
| | - Unn K. Haukvik
- NORMENT, KG Jebsen Centre for Psychosis Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway
| | - Katrin Hegenscheid
- Department of Diagnostic Radiology and Neuroradiology, University of Greifswald, Greifswald, Germany
| | - Andreas Heinz
- Department of Psychiatry and Psychotherapy, Charité, Universitaetsmedizin Berlin, Charitè Campus Mitte, Berlin, Germany
| | - Ian B. Hickie
- The Brain and Mind Research Institute, University of Sydney, Sydney, Australia
| | - Beng-Choon Ho
- Department of Psychiatry, University of Iowa, Iowa City, IA USA
| | - David Hoehn
- Max Planck Institute of Psychiatry, Munich, Germany
| | - Pieter J. Hoekstra
- Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Marisa Hollinshead
- MGH/HMS Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA USA
- Center for Brain Science, Harvard University, Cambridge, MA USA
| | - Avram J. Holmes
- MGH/HMS Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA USA
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA USA
- Center for Brain Science, Harvard University, Cambridge, MA USA
| | - Georg Homuth
- Interfaculty Institute for Genetics and Functional Genomics, University of Greifswald, Greifswald, Germany
| | - Martine Hoogman
- Department of Human Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands
| | - L. Elliot Hong
- Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD USA
| | - Norbert Hosten
- Department of Diagnostic Radiology and Neuroradiology, University of Greifswald, Greifswald, Germany
| | - Jouke-Jan Hottenga
- Department of Biological Psychology, VU University, Neuroscience Campus, Amsterdam, The Netherlands
| | | | - Kristy S. Hwang
- Oakland University William Beaumont School of Medicine, Rochester Hills, MI USA
| | | | - Mark Jenkinson
- Oxford Centre for Functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK
| | - Caroline Johnston
- National Institute of Health Research Biomedical Research Centre for Mental Health, South London and Maudsley National Health Service Foundation Trust, London, UK
- King’s College London, Institute of Psychiatry, London, UK
| | - Erik G. Jönsson
- Department of Clinical Neuroscience, Karolinska Institutet and Hospital, Stockholm, Sweden
| | - René S. Kahn
- Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Dalia Kasperaviciute
- Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
| | - Sinead Kelly
- Neuropsychiatric Genetics Research Group, Department of Psychiatry, Institute for Molecular Medicine and Trinity College Institute for Neuroscience, Trinity College, Dublin, Ireland
| | - Sungeun Kim
- Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine, Indianapolis, IN USA
| | - Peter Kochunov
- Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD USA
| | - Laura Koenders
- EMGO + Institute, VU University Medical Center, Amsterdam, The Netherlands
| | - Bernd Krämer
- Center for Translational Research in Systems Neuroscience and Psychiatry, Department of Psychiatry, Georg August University, Goettingen, Germany
| | - John B. J. Kwok
- Neuroscience Research Australia, Sydney, Australia
- School of Medical Sciences, University of New South Wales, Sydney, Australia
- School of Medical Sciences, University of New South Wales, Kensington, NSW Australia
| | - Jim Lagopoulos
- The Brain and Mind Research Institute, University of Sydney, Sydney, Australia
| | - Gonzalo Laje
- Maryland Institute for Neuroscience and Development (MIND), Chevy Chase, MD USA
| | - Mikael Landen
- Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
| | | | - John Lauriello
- Department of Psychiatry, University of Missouri, Columbia, MO USA
| | - Stephen M. Lawrie
- Division of Psychiatry, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, UK
| | - Phil H. Lee
- Broad Institute of Harvard and MIT, Boston, MA USA
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA USA
- Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA USA
| | - Stephanie Le Hellard
- NORMENT, KG Jebsen Centre for Psychosis Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Dr Einar Martens Research Group for Biological Psychiatry, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Herve Lemaître
- Research Unit 1000, Neuroimaging and Psychiatry, INSERM-CEA-Faculté de Médecine Paris Sud University-Paris Descartes University, Maison de Solenn Paris, SHFJ Orsay, Paris, France
| | - Cassandra D. Leonardo
- Imaging Genetics Center, Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, 2001 N. Soto Street, Los Angeles, CA 90033 USA
| | - Chiang-shan Li
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT USA
| | - Benny Liberg
- Department of Clinical Neuroscience, Karolinska Institutet and Hospital, Stockholm, Sweden
| | - David C. Liewald
- Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, 7 George Square, Edinburgh, UK
| | - Xinmin Liu
- Mood and Anxiety Disorders Section, Human Genetics Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, US Dept of Health and Human Services, Bethesda, MD USA
- Taub Institute for Research on Alzheimer Disease and the Aging Brain, Columbia University Medical Center, New York, NY USA
| | - Lorna M. Lopez
- Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, 7 George Square, Edinburgh, UK
- Department of Psychology, The University of Edinburgh, Edinburgh, UK
| | - Eva Loth
- MRC-SGDP Centre, Institute of Psychiatry, King’s College London, London, UK
| | | | - Michelle Luciano
- Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, 7 George Square, Edinburgh, UK
| | - Fabio Macciardi
- Department of Psychiatry and Human Behavior, University of California, Irvine, CA USA
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
| | | | - Glenda M. MacQueen
- Mathison Centre for Mental Health Research and Education, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta Canada
| | - Ulrik F. Malt
- Department of Psychosomatic Medicine, Oslo University Hospital, Oslo, Norway
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - René Mandl
- Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Dara S. Manoach
- MGH/HMS Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA USA
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA USA
| | - Jean-Luc Martinot
- Research Unit 1000, Neuroimaging and Psychiatry, INSERM-CEA-Faculté de Médecine Paris Sud University-Paris Descartes University, Maison de Solenn Paris, SHFJ Orsay, Paris, France
| | - Mar Matarin
- Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
| | - Karen A. Mather
- Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales Medicine, Sydney, New South Wales Australia
| | - Manuel Mattheisen
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
- Department of Genomic Mathematics, University of Bonn, Bonn, Germany
| | - Morten Mattingsdal
- NORMENT, KG Jebsen Centre for Psychosis Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Research Unit, Sorlandet Hospital HF, Kristiansand, Norway
| | - Andreas Meyer-Lindenberg
- Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Colm McDonald
- Clinical Neuroimaging Laboratory, National University of Ireland Galway, University Road, Galway, Ireland
| | - Andrew M. McIntosh
- Division of Psychiatry, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, UK
| | - Francis J. McMahon
- Mood and Anxiety Disorders Section, Human Genetics Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, US Dept of Health and Human Services, Bethesda, MD USA
| | - Katie L. McMahon
- Centre for Advanced Imaging, University of Queensland, Brisbane, Australia
| | | | - Ingrid Melle
- NORMENT, KG Jebsen Centre for Psychosis Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
| | - Yuri Milaneschi
- EMGO + Institute, VU University Medical Center, Amsterdam, The Netherlands
- Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, Baltimore, MD USA
| | - Sebastian Mohnke
- Department of Psychiatry and Psychotherapy, Charité, Universitaetsmedizin Berlin, Charitè Campus Mitte, Berlin, Germany
| | - Grant W. Montgomery
- Genetic Epidemiology Laboratory, Queensland Institute of Medical Research, Brisbane, Australia
| | - Derek W. Morris
- Neuropsychiatric Genetics Research Group, Department of Psychiatry, Institute for Molecular Medicine and Trinity College Institute for Neuroscience, Trinity College, Dublin, Ireland
| | - Eric K. Moses
- Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX USA
- Centre for Genetic Origins of Health and Disease, The University of Western Australia, Perth, Australia
| | - Bryon A. Mueller
- Department of Psychiatry, University of Minnesota Medical Center, Minneapolis, MN USA
| | - Susana Muñoz Maniega
- Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, 7 George Square, Edinburgh, UK
- Scottish Imaging Network, A Platform for Scientific Excellence (SINAPSE) Collaboration, Scotland, UK
- Brain Research Imaging Centre, The University of Edinburgh, Edinburgh, UK
| | - Thomas W. Mühleisen
- Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany
- Institute of Human Genetics, University of Bonn, Bonn, Germany
- Institute for Neuroscience and Medicine (INM-1), Centre Jülich, Jülich, Germany
| | - Bertram Müller-Myhsok
- Max Planck Institute of Psychiatry, Munich, Germany
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - Benson Mwangi
- Department of Psychiatry and Behavioral Sciences, University of Texas Medical School, Houston, TX USA
- University of Texas Center of Excellence on Mood Disorders, Department of Psychiatry, UT Medical School, Houston, TX USA
| | - Matthias Nauck
- Institute of Clinical Chemistry and Laboratory Medicine, University of Greifswald, Greifswald, Germany
| | - Kwangsik Nho
- Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine, Indianapolis, IN USA
| | - Thomas E. Nichols
- Department of Statistics & Warwick Manufacturing Group, The University of Warwick, Coventry, UK
| | - Lars-Göran Nilsson
- Department of Psychology, Stockholm University, Stockholm, Sweden
- Stockholm Brain Institute, Stockholm, Sweden
| | - Allison C. Nugent
- Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, Bethesda, MD USA
| | - Lars Nyberg
- Umeå Center for Functional Brain Imaging (UFBI), Umeå University, Umeå, Sweden
| | - Rene L. Olvera
- Department of Psychiatry, UT Health Science Center at San Antonio, San Antonio, TX USA
| | - Jaap Oosterlaan
- Department of Clinical Neuropsychology, VU University, Amsterdam, The Netherlands
| | - Roel A. Ophoff
- Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
- Center for Neurobehavioral Genetics, University of California, Los Angeles, CA USA
| | - Massimo Pandolfo
- Department of Neurology, Hopital Erasme, Universite Libre de Bruxelles, 1070 Brussels, Belgium
| | | | - Martina Papmeyer
- Division of Psychiatry, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, UK
| | - Tomas Paus
- Rotman Research Institute, University of Toronto, Toronto, ON Canada
| | - Zdenka Pausova
- The Hospital for Sick Children, University of Toronto, Toronto, ON Canada
| | - Godfrey D. Pearlson
- Department of Psychiatry and Psychotherapy, University of Greifswald, Greifswald, Germany
- Departments of Psychiatry and Neurobiology, Yale University School of Medicine, New Haven, CT USA
| | - Brenda W. Penninx
- Department of Psychiatry and Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
- EMGO + Institute, VU University Medical Center, Amsterdam, The Netherlands
| | - Charles P. Peterson
- Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX USA
| | - Andrea Pfennig
- Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Dresden, Germany
| | - Mary Phillips
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA USA
| | - G. Bruce Pike
- Department of Radiology, University of Calgary, Calgary, Alberta Canada
| | - Jean-Baptiste Poline
- Hellen Wills Neuroscience Institute, Brain Imaging Center, University of California at Berkeley, Berkeley, CA USA
| | - Steven G. Potkin
- Department of Psychiatry and Human Behavior, University of California, Irvine, CA USA
| | - Benno Pütz
- Max Planck Institute of Psychiatry, Munich, Germany
| | - Adaikalavan Ramasamy
- Department of Medical and Molecular Genetics, King’s College London, London, UK
- Reta Lila Weston Institute and Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
| | - Jerod Rasmussen
- Department of Psychiatry and Human Behavior, University of California, Irvine, CA USA
| | - Marcella Rietschel
- Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Mark Rijpkema
- Donders Institute for Brain, Cognition and Behaviour, Department of Cognitive Neuroscience, Radboud University Medical Centre, Nijmegen, The Netherlands
| | - Shannon L. Risacher
- Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine, Indianapolis, IN USA
- Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN USA
| | - Joshua L. Roffman
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA USA
| | - Roberto Roiz-Santiañez
- Department of Psychiatry, Marqués de Valdecilla University Hospital, IFIMAV, School of Medicine, University of Cantabria, Santander, Spain
- Centro Investigación Biomédica en Red Salud Mental (CIBERSAM), Madrid, Spain
| | - Nina Romanczuk-Seiferth
- Department of Psychiatry and Psychotherapy, Charité, Universitaetsmedizin Berlin, Charitè Campus Mitte, Berlin, Germany
| | - Emma J. Rose
- Transdisciplinary and Translational Prevention Program, RTI International, Baltimore, MD USA
| | - Natalie A. Royle
- Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, 7 George Square, Edinburgh, UK
- Brain Research Imaging Centre, The University of Edinburgh, Edinburgh, UK
| | - Dan Rujescu
- Department of Psychiatry, University of Halle, Halle, Germany
| | - Mina Ryten
- Department of Molecular Neuroscience, UCL Institute, London, UK
- Department of Medical and Molecular Genetics, King’s College London, London, UK
| | - Perminder S. Sachdev
- Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales Medicine, Sydney, New South Wales Australia
- Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, New South Wales Australia
| | - Alireza Salami
- Umeå Center for Functional Brain Imaging (UFBI), Umeå University, Umeå, Sweden
- Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden
| | | | - Jonathan Savitz
- Laureate Institute for Brain Research, Tulsa, OK USA
- Faculty of Community Medicine, University of Tulsa, Tulsa, OK USA
| | - Andrew J. Saykin
- Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine, Indianapolis, IN USA
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN USA
| | - Cathy Scanlon
- Clinical Neuroimaging Laboratory, National University of Ireland Galway, University Road, Galway, Ireland
| | - Lianne Schmaal
- Department of Psychiatry and Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
| | - Hugo G. Schnack
- Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | | | - S. Charles Schulz
- Department of Psychiatry, University of Minnesota Medical Center, Minneapolis, MN USA
| | - Remmelt Schür
- Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Larry Seidman
- Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA USA
- Department of Psychiatry, Harvard Medical School, Harvard University, Cambridge, MA USA
| | - Li Shen
- Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN USA
- Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine, Indianapolis, IN USA
| | | | - Andrew Simmons
- Department of Neuroimaging, Institute of Psychiatry, King’s College London, London, UK
- NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Trust and Institute of Psychiatry, King’s College London, London, UK
| | - Sanjay M. Sisodiya
- Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
| | - Colin Smith
- Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK
| | - Jordan W. Smoller
- Broad Institute of Harvard and MIT, Boston, MA USA
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA USA
- Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA USA
| | - Jair C. Soares
- Department of Psychiatry and Behavioral Sciences, University of Texas Medical School, Houston, TX USA
| | - Scott R. Sponheim
- Department of Psychiatry, University of Minnesota Medical Center, Minneapolis, MN USA
- Minneapolis VA Health Care System, Minneapolis, MN USA
| | - Emma Sprooten
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT USA
| | - John M. Starr
- Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, 7 George Square, Edinburgh, UK
- Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, UK
| | - Vidar M. Steen
- NORMENT, KG Jebsen Centre for Psychosis Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Dr Einar Martens Research Group for Biological Psychiatry, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Stephen Strakowski
- Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH USA
| | - Lachlan Strike
- Genetic Epidemiology Laboratory, Queensland Institute of Medical Research, Brisbane, Australia
| | - Jessika Sussmann
- Division of Psychiatry, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, UK
| | | | - Alexander Teumer
- Interfaculty Institute for Genetics and Functional Genomics, University of Greifswald, Greifswald, Germany
| | - Arthur W. Toga
- Imaging Genetics Center, Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, 2001 N. Soto Street, Los Angeles, CA 90033 USA
| | - Diana Tordesillas-Gutierrez
- Department of Psychiatry, Marqués de Valdecilla University Hospital, IFIMAV, School of Medicine, University of Cantabria, Santander, Spain
- Centro Investigación Biomédica en Red Salud Mental (CIBERSAM), Madrid, Spain
| | - Daniah Trabzuni
- Department of Molecular Neuroscience, UCL Institute, London, UK
- Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
| | - Sarah Trost
- Center for Translational Research in Systems Neuroscience and Psychiatry, Department of Psychiatry, Georg August University, Goettingen, Germany
| | - Jessica Turner
- The Mind Research Network, Albuquerque, NM USA
- Department of Psychology and Neuroscience Institute, Georgia State University, Atlanta, GA USA
| | | | - Nic J. van der Wee
- Department of Psychiatry and Leiden Institute for Brain and Cognition, Leiden University Medical Center, Leiden, The Netherlands
| | - Kristel van Eijk
- Department of Psychiatry, Rudolf Magnus Institute, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Theo G. M. van Erp
- Department of Psychiatry and Human Behavior, University of California, Irvine, CA USA
| | | | - Dennis van ‘t Ent
- Department of Biological Psychology, VU University, Neuroscience Campus, Amsterdam, The Netherlands
| | - Marie-Jose van Tol
- Behavioural and Cognitive Neuroscience Neuroimaging Center, University Medical Center Groningen, Groningen, The Netherlands
| | - Maria C. Valdés Hernández
- Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, 7 George Square, Edinburgh, UK
- Brain Research Imaging Centre, The University of Edinburgh, Edinburgh, UK
| | - Dick J. Veltman
- Department of Psychiatry and Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
| | - Amelia Versace
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA USA
| | - Henry Völzke
- Institute for Community Medicine, University of Greifswald, Greifswald, Germany
| | - Robert Walker
- Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
| | - Henrik Walter
- Department of Psychiatry and Psychotherapy, Charité, Universitaetsmedizin Berlin, Charitè Campus Mitte, Berlin, Germany
- Berlin School of Mind and Brain, Humboldt University Berlin, Berlin, Germany
| | - Lei Wang
- Departments of Psychiatry and Behavioral Sciences and Radiology, Northwestern University, Chicago, IL USA
| | - Joanna M. Wardlaw
- Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, 7 George Square, Edinburgh, UK
- Scottish Imaging Network, A Platform for Scientific Excellence (SINAPSE) Collaboration, Scotland, UK
- Brain Research Imaging Centre, The University of Edinburgh, Edinburgh, UK
| | - Michael E. Weale
- Department of Medical and Molecular Genetics, King’s College London, London, UK
| | - Michael W. Weiner
- Departments of Radiology, Medicine, Psychiatry, University of California, San Francisco, CA USA
| | - Wei Wen
- Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales Medicine, Sydney, New South Wales Australia
| | - Lars T. Westlye
- NORMENT, KG Jebsen Centre for Psychosis Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Department of Psychology, University of Oslo, Oslo, Norway
| | - Heather C. Whalley
- Division of Psychiatry, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, UK
| | - Christopher D. Whelan
- Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland
| | - Tonya White
- Department of Child and Adolescent Psychiatry, Erasmus University Medical Centre, Rotterdam, The Netherlands
| | - Anderson M. Winkler
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT USA
- Oxford Centre for Functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK
| | - Katharina Wittfeld
- German Center for Neurodegenerative Diseases (DZNE), University of Greifswald, Greifswald, Germany
| | - Girma Woldehawariat
- Mood and Anxiety Disorders Section, Human Genetics Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, US Dept of Health and Human Services, Bethesda, MD USA
| | | | - David Zilles
- Center for Translational Research in Systems Neuroscience and Psychiatry, Department of Psychiatry, Georg August University, Goettingen, Germany
| | - Marcel P. Zwiers
- Donders Institute for Brain, Cognition and Behaviour, Department of Cognitive Neuroscience, Radboud University Medical Centre, Nijmegen, The Netherlands
- Radboud University NijmegenDonders Institute for Brain, Cognition and Behavior, Centre for Cognitive Neuroimaging, Nijmegen, The Netherlands
| | - Anbupalam Thalamuthu
- Centre for Healthy Brain Ageing, Psychiatry, University of New South Wales (UNSW), Sydney, Australia
| | - Peter R. Schofield
- Neuroscience Research Australia, Sydney, Australia
- School of Medical Sciences, University of New South Wales, Sydney, Australia
| | - Nelson B. Freimer
- Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, CA USA
| | | | - Wayne Drevets
- Janssen Research & Development, of Johnson & Johnson, Inc., 1125 Trenton-Harbourton Road, Titusville, NJ 08560 USA
| | - the Alzheimer’s Disease Neuroimaging Initiative, EPIGEN Consortium, IMAGEN Consortium, Saguenay Youth Study (SYS) Group
- Imaging Genetics Center, Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, 2001 N. Soto Street, Los Angeles, CA 90033 USA
- Genetic Epidemiology Laboratory, Queensland Institute of Medical Research, Brisbane, Australia
- Broad Institute of Harvard and MIT, Boston, MA USA
- Department of Human Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands
- Donders Institute for Brain, Cognition and Behaviour, Department of Cognitive Neuroscience, Radboud University Medical Centre, Nijmegen, The Netherlands
- Human Genetics and Cognitive Functions, Institut Pasteur, Paris, France
- CNRS URA 2182 ‘Genes, synapses and cognition’, Institut Pasteur, Paris, France
- Sorbonne Paris Cité, Human Genetics and Cognitive Functions, Université Paris Diderot, Paris, France
- Olin Neuropsychiatry Research Center, Institute of Living, Hartford Hospital, Hartford, CT USA
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT USA
- Department of Psychiatry and Psychotherapy, University of Greifswald, Greifswald, Germany
- NORMENT, KG Jebsen Centre for Psychosis Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland
- Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX USA
- Department of Psychiatry, University of Iowa, Iowa City, IA USA
- Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA USA
- Centre for Cognitive Ageing and Cognitive Epidemiology, The University of Edinburgh, 7 George Square, Edinburgh, UK
- Scottish Imaging Network, A Platform for Scientific Excellence (SINAPSE) Collaboration, Scotland, UK
- Brain Research Imaging Centre, The University of Edinburgh, Edinburgh, UK
- Max Planck Institute of Psychiatry, Munich, Germany
- The Mind Research Network, Albuquerque, NM USA
- Department of Biological Psychology, VU University, Neuroscience Campus, Amsterdam, The Netherlands
- Department of Cognitive Neuroscience, Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behavior, Nijmegen, The Netherlands
- Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
- Massachusetts General Hospital, Boston, MA USA
- Karakter Child and Adolescent Psychiatry University Center, Nijmegen, The Netherlands
- N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences, Gubkin str. 3, Moscow, 119991 Russia
- Department of Psychiatry, University of New Mexico, Albuquerque, NM USA
- Department of Electrical and Computer Engineering, University of New Mexico, Albuquerque, NM USA
- Clinical Neuroimaging Laboratory, National University of Ireland Galway, University Road, Galway, Ireland
- Center for Neurobehavioral Genetics, University of California, Los Angeles, CA USA
- The Kimel Family Translational Imaging Genetics Laboratory, The Centre for Addiction and Mental Health, Toronto, ON Canada
- Dr Einar Martens Research Group for Biological Psychiatry, Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
- Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany
- Institute of Human Genetics, University of Bonn, Bonn, Germany
- Institute for Neuroscience and Medicine (INM-1), Centre Jülich, Jülich, Germany
- Division of Medical Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland
- Department of Psychiatry, Marqués de Valdecilla University Hospital, IFIMAV, School of Medicine, University of Cantabria, Santander, Spain
- Centro Investigación Biomédica en Red Salud Mental (CIBERSAM), Madrid, Spain
- Department of Psychology, The University of Edinburgh, Edinburgh, UK
- Department of Neurology, Hopital Erasme, Universite Libre de Bruxelles, 1070 Brussels, Belgium
- School of Psychology, University of Queensland, Brisbane, QLD 4072 Australia
- Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
- Neuropsychiatric Genetics Research Group, Department of Psychiatry, Institute for Molecular Medicine and Trinity College Institute for Neuroscience, Trinity College, Dublin, Ireland
- MGH/HMS Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA USA
- University Hospital C.G. Carus, Department of Child and Adolescent Psychiatry, Dresden University of Technology, Dresden, Germany
- Department of Psychiatry and Psychotherapy, Charité, Universitaetsmedizin Berlin, Charitè Campus Mitte, Berlin, Germany
- Department of Psychology, University of Oslo, Oslo, Norway
- Max Planck Institute for Psycholinguistics, 6500 AH Nijmegen, The Netherlands
- Research Imaging Institute, UT Health Science Center at San Antonio, San Antonio, TX USA
- South Texas Veterans Health Care Center, San Antonio, TX USA
- Neurospin, Commissariat à l’Energie Atomique, Paris, France
- Department of Psychiatry, Massachusetts General Hospital, Boston, MA USA
- German Center for Neurodegenerative Diseases (DZNE), University of Greifswald, Greifswald, Germany
- Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
- Center for Translational Research in Systems Neuroscience and Psychiatry, Department of Psychiatry, Georg August University, Goettingen, Germany
- Division of Psychiatry, Royal Edinburgh Hospital, University of Edinburgh, Edinburgh, UK
- Department of Molecular Neuroscience, UCL Institute, London, UK
- Department of Diagnostic Radiology and Neuroradiology, University of Greifswald, Greifswald, Germany
- Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- Interfaculty Institute for Genetics and Functional Genomics, University of Greifswald, Greifswald, Germany
- National Institute of Health Research Biomedical Research Centre for Mental Health, South London and Maudsley National Health Service Foundation Trust, London, UK
- King’s College London, Institute of Psychiatry, London, UK
- Department of Clinical Neuroscience, Karolinska Institutet and Hospital, Stockholm, Sweden
- Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK
- Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN USA
- Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine, Indianapolis, IN USA
- Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD USA
- Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA USA
- Mood and Anxiety Disorders Section, Human Genetics Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, US Dept of Health and Human Services, Bethesda, MD USA
- Taub Institute for Research on Alzheimer Disease and the Aging Brain, Columbia University Medical Center, New York, NY USA
- MRC-SGDP Centre, Institute of Psychiatry, King’s College London, London, UK
- Department of Psychiatry and Human Behavior, University of California, Irvine, CA USA
- Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales Medicine, Sydney, New South Wales Australia
- Department of Biomedicine, Aarhus University, Aarhus, Denmark
- Department of Genomic Mathematics, University of Bonn, Bonn, Germany
- Research Unit, Sorlandet Hospital HF, Kristiansand, Norway
- Centre for Advanced Imaging, University of Queensland, Brisbane, Australia
- Ludwig-Maximilians-University (LMU), Munich, Germany
- Department of Psychiatry and Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
- Centre for Genetic Origins of Health and Disease, The University of Western Australia, Perth, Australia
- Department of Psychiatry, University of Minnesota Medical Center, Minneapolis, MN USA
- Department of Psychology, Stockholm University, Stockholm, Sweden
- Umeå Center for Functional Brain Imaging (UFBI), Umeå University, Umeå, Sweden
- Department of Psychiatry, UT Health Science Center at San Antonio, San Antonio, TX USA
- Rotman Research Institute, University of Toronto, Toronto, ON Canada
- The Hospital for Sick Children, University of Toronto, Toronto, ON Canada
- Department of Psychiatry and Leiden Institute for Brain and Cognition, Leiden University Medical Center, Leiden, The Netherlands
- Department of Medical and Molecular Genetics, King’s College London, London, UK
- Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, New South Wales Australia
- Laureate Institute for Brain Research, Tulsa, OK USA
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN USA
- Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA USA
- Department of Neuroimaging, Institute of Psychiatry, King’s College London, London, UK
- NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Trust and Institute of Psychiatry, King’s College London, London, UK
- Minneapolis VA Health Care System, Minneapolis, MN USA
- Behavioural and Cognitive Neuroscience Neuroimaging Center, University Medical Center Groningen, Groningen, The Netherlands
- Institute for Community Medicine, University of Greifswald, Greifswald, Germany
- Departments of Radiology, Medicine, Psychiatry, University of California, San Francisco, CA USA
- Department of Child and Adolescent Psychiatry, Erasmus University Medical Centre, Rotterdam, The Netherlands
- Radboud University NijmegenDonders Institute for Brain, Cognition and Behavior, Centre for Cognitive Neuroimaging, Nijmegen, The Netherlands
- Oxford Centre for Functional MRI of the Brain (FMRIB), University of Oxford, Oxford, UK
- Neuroscience Research Australia, Sydney, Australia
- School of Medical Sciences, University of New South Wales, Sydney, Australia
- Center for Brain Science, Harvard University, Cambridge, MA USA
- The Brain and Mind Research Institute, University of Sydney, Sydney, Australia
- Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, UK
- Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
- Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK
- Department Early Psychosis, Academic Psychiatric Centre, AMC, UvA, Amsterdam, Netherlands
- EMGO + Institute, VU University Medical Center, Amsterdam, The Netherlands
- Cognitive Science Department, UC San Diego, La Jolla, CA USA
- Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway
- Department of Clinical Neuropsychology, VU University, Amsterdam, The Netherlands
- Reta Lila Weston Institute and Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
- Department of Neurology and NeuroSurgery, McGill University, Montreal, Quebec Canada
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA USA
- Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia Canada
- Department of Psychiatry, University of Oxford, Oxford, UK
- Department of Psychiatry and Behavioral Sciences, University of Texas Medical School, Houston, TX USA
- University of Texas Center of Excellence on Mood Disorders, Department of Psychiatry, UT Medical School, Houston, TX USA
- Department of Psychiatry and Biobehavioral Sciences and the Center for Neurobehavioral Genetics, The Semel Institute for Neuroscience and Human Behavior, UCLA, Los Angeles, CA USA
- Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, Baltimore, MD USA
- Berlin School of Mind and Brain, Humboldt University Berlin, Berlin, Germany
- Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Dresden, Germany
- Department of Psychiatry and Psychotherapy, Helios Hospital Stralsund, Stralsund, Germany
- Department of Psychiatry, Harvard Medical School, Harvard University, Cambridge, MA USA
- Department of Psychiatry, Brown University, Providence, RI USA
- Psychosis Research Unit, Mount Sinai School of Medicine, New York, NY USA
- Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH USA
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA USA
- Philadelphia Veterans Administration Medical Center, Philadelphia, PA USA
- Department of Psychiatry and Psychotherapy, University Regensburg, Regensburg, Germany
- Department of Psychiatry and Psychotherapy, Trinity College, University Dublin, Dublin, Germany
- Stockholm Brain Institute, Stockholm, Sweden
- Department of Psychology and Neuroscience Institute, Georgia State University, Atlanta, GA USA
- Department of Psychology, Neuroscience and Behaviour, McMaster University, Hamilton, ON Canada
- Department of Psychology, University of New Mexico, Albuquerque, NM USA
- Department of Psychosomatic Medicine, Oslo University Hospital, Oslo, Norway
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN USA
- Department of Radiology, University of Calgary, Calgary, Alberta Canada
- Department of Statistics & Warwick Manufacturing Group, The University of Warwick, Coventry, UK
- Departments of Psychiatry and Behavioral Sciences and Radiology, Northwestern University, Chicago, IL USA
- Electrical Engineering, Vanderbilt University, Nashville, TN USA
- Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, Bethesda, MD USA
- Institute of Clinical Chemistry and Laboratory Medicine, University of Greifswald, Greifswald, Germany
- Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON Canada
- Faculty of Community Medicine, University of Tulsa, Tulsa, OK USA
- Maryland Institute for Neuroscience and Development (MIND), Chevy Chase, MD USA
- Mathison Centre for Mental Health Research and Education, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta Canada
- Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK
- Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK
- School of Medical Sciences, University of New South Wales, Kensington, NSW Australia
- Oakland University William Beaumont School of Medicine, Rochester Hills, MI USA
- CHU Sainte Justine University Hospital Research Center, Montreal, QC Canada
- Addictions Department, King’s Health Partners, King’s College London, London, UK
- South Texas Veterans Health Care System, San Antonio, TX USA
- Research Unit 1000, Neuroimaging and Psychiatry, INSERM-CEA-Faculté de Médecine Paris Sud University-Paris Descartes University, Maison de Solenn Paris, SHFJ Orsay, Paris, France
- Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
- Department of Psychiatry, Rudolf Magnus Institute, University Medical Center Utrecht, Utrecht, The Netherlands
- School of Mathematics and Statistics, University of Sydney, Sydney, Australia
- School of Medicine, University of Nottingham, Nottingham, UK
- Department of Psychiatry, Stanford University School of Medicine, Stanford, CA USA
- Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden
- Hellen Wills Neuroscience Institute, Brain Imaging Center, University of California at Berkeley, Berkeley, CA USA
- Department of Psychiatry, University of Missouri, Columbia, MO USA
- Departments of Psychiatry and Neurobiology, Yale University School of Medicine, New Haven, CT USA
- Mayo Clinic, Rochester, MN USA
- Transdisciplinary and Translational Prevention Program, RTI International, Baltimore, MD USA
- Department of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY USA
- Department of Psychiatry, University of Halle, Halle, Germany
- Advanced Biomedical Informatics Group, llc., Iowa City, IA USA
- Program in Neurogenetics, Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095 Netherlands
- QIMR Berghofer Medical Research Institute, Quantitative Genetics, Brisbane, Australia
- QIMR Berghofer Medical Research Institute, Genetic Epidemiology, Brisbane, Australia
- QIMR Berghofer Medical Research Institute, Neuroimaging Genetics, Brisbane, Australia
- Department of Psychology, UCLA, Los Angeles, CA USA
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
- Dr. E. Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
- Department of Psychiatry, UHC University of Vermont, Bergen, VT USA
- Centre for Healthy Brain Ageing, Psychiatry, University of New South Wales (UNSW), Sydney, Australia
- Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, CA USA
- School of Psychology, University of Exeter, Exeter, UK
- Janssen Research & Development, of Johnson & Johnson, Inc., 1125 Trenton-Harbourton Road, Titusville, NJ 08560 USA
| |
Collapse
|
37
|
Douet V, Chang L, Pritchett A, Lee K, Keating B, Bartsch H, Jernigan TL, Dale A, Akshoomoff N, Murray S, Bloss C, Kennedy DN, Amaral D, Gruen J, Kaufmann WE, Casey BJ, Sowell E, Ernst T. Schizophrenia-risk variant rs6994992 in the neuregulin-1 gene on brain developmental trajectories in typically developing children. Transl Psychiatry 2014; 4:e392. [PMID: 24865593 PMCID: PMC4035723 DOI: 10.1038/tp.2014.41] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/11/2014] [Accepted: 04/22/2014] [Indexed: 11/09/2022] Open
Abstract
The neuregulin-1 (NRG1) gene is one of the best-validated risk genes for schizophrenia, and psychotic and bipolar disorders. The rs6994992 variant in the NRG1 promoter (SNP8NRG243177) is associated with altered frontal and temporal brain macrostructures and/or altered white matter density and integrity in schizophrenic adults, as well as healthy adults and neonates. However, the ages when these changes begin and whether neuroimaging phenotypes are associated with cognitive performance are not fully understood. Therefore, we investigated the association of the rs6994992 variant on developmental trajectories of brain macro- and microstructures, and their relationship with cognitive performance. A total of 972 healthy children aged 3-20 years had the genotype available for the NRG1-rs6994992 variant, and were evaluated with magnetic resonance imaging (MRI) and neuropsychological tests. Age-by-NRG1-rs6994992 interactions and genotype effects were assessed using a general additive model regression methodology, covaried for scanner type, socioeconomic status, sex and genetic ancestry factors. Compared with the C-carriers, children with the TT-risk-alleles had subtle microscopic and macroscopic changes in brain development that emerge or reverse during adolescence, a period when many psychiatric disorders are manifested. TT-children at late adolescence showed a lower age-dependent forniceal volume and lower fractional anisotropy; however, both measures were associated with better episodic memory performance. To our knowledge, we provide the first multimodal imaging evidence that genetic variation in NRG1 is associated with age-related changes on brain development during typical childhood and adolescence, and delineated the altered patterns of development in multiple brain regions in children with the T-risk allele(s).
Collapse
Affiliation(s)
- V Douet
- Department of Medicine, John A. Burns School of Medicine, University of Hawaii and Queen's Medical Center, Honolulu, HI, USA,Department of Medicine, John A. Burns School of Medicine, University of Hawaii and Queen's Medical Center, 1356 Lusitana Street, UH Tower, Room 716, Honolulu, HI 96813, USA. E-mail:
| | - L Chang
- Department of Medicine, John A. Burns School of Medicine, University of Hawaii and Queen's Medical Center, Honolulu, HI, USA
| | - A Pritchett
- Department of Medicine, John A. Burns School of Medicine, University of Hawaii and Queen's Medical Center, Honolulu, HI, USA
| | - K Lee
- Department of Medicine, John A. Burns School of Medicine, University of Hawaii and Queen's Medical Center, Honolulu, HI, USA
| | - B Keating
- Department of Medicine, John A. Burns School of Medicine, University of Hawaii and Queen's Medical Center, Honolulu, HI, USA
| | - H Bartsch
- Department of Radiology, University of California, San Diego, La Jolla, CA, USA
| | - T L Jernigan
- Department of Radiology, University of California, San Diego, La Jolla, CA, USA,Department of Psychiatry and Department of Cognitive Science, Center for Human Development, University of California, San Diego, La Jolla, CA, USA
| | - A Dale
- Department of Radiology, University of California, San Diego, La Jolla, CA, USA,Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA
| | - N Akshoomoff
- Department of Radiology, University of California, San Diego, La Jolla, CA, USA,Department of Psychiatry and Department of Cognitive Science, Center for Human Development, University of California, San Diego, La Jolla, CA, USA
| | - S Murray
- Scripps Genomic Medicine and Scripps Translational Science Institute, The Scripps Research Institute, La Jolla, CA, USA
| | - C Bloss
- Scripps Genomic Medicine and Scripps Translational Science Institute, The Scripps Research Institute, La Jolla, CA, USA
| | - D N Kennedy
- Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, USA
| | - D Amaral
- Departments of Psychiatry and Behavioral Sciences, University of California, Davis, CA, USA
| | - J Gruen
- Departments of Pediatrics and Investigative Medicine, Child Health Research Center, Yale University School of Medicine, New Haven, CT, USA
| | - W E Kaufmann
- Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - B J Casey
- Sackler Institute for Developmental Psychobiology, Weil Cornell Medical College, New York, NY, USA
| | - E Sowell
- Department of Pediatrics, University of Southern California, and Children's Hospital, Los Angeles, CA, USA
| | - T Ernst
- Department of Medicine, John A. Burns School of Medicine, University of Hawaii and Queen's Medical Center, Honolulu, HI, USA
| |
Collapse
|
38
|
Sprooten E, Knowles EE, McKay DR, Göring HH, Curran JE, Kent JW, Carless MA, Dyer TD, Drigalenko EI, Olvera RL, Fox PT, Almasy L, Duggirala R, Kochunov P, Blangero J, Glahn DC. Common genetic variants and gene expression associated with white matter microstructure in the human brain. Neuroimage 2014; 97:252-61. [PMID: 24736177 DOI: 10.1016/j.neuroimage.2014.04.021] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2014] [Revised: 03/29/2014] [Accepted: 04/07/2014] [Indexed: 12/29/2022] Open
Abstract
Identifying genes that contribute to white matter microstructure should provide insights into the neurobiological processes that regulate white matter development, plasticity and pathology. We detected five significant SNPs using genome-wide association analysis on a global measure of fractional anisotropy in 776 individuals from large extended pedigrees. Genetic correlations and genome-wide association results indicated that the genetic signal was largely homogeneous across white matter regions. Using RNA transcripts derived from lymphocytes in the same individuals, we identified two genes (GNA13 and CCDC91) that are likely to be cis-regulated by top SNPs, and whose expression levels were also genetically correlated with fractional anisotropy. A transcript of HTR7 was phenotypically associated with FA, and was associated with an intronic genome-wide significant SNP. These results encourage further research in the mechanisms by which GNA13, HTR7 and CCDC91 influence brain structure, and emphasize a role for g-protein signaling in the development and maintenance of white matter microstructure in health and disease.
Collapse
Affiliation(s)
- Emma Sprooten
- Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT, USA; Olin Neuropsychiatry Research Center, Institute of Living, Hartford Hospital, 200 Retreat Avenue, CT, USA.
| | - Emma E Knowles
- Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT, USA; Olin Neuropsychiatry Research Center, Institute of Living, Hartford Hospital, 200 Retreat Avenue, CT, USA
| | - D Reese McKay
- Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT, USA; Olin Neuropsychiatry Research Center, Institute of Living, Hartford Hospital, 200 Retreat Avenue, CT, USA
| | - Harald H Göring
- Department of Genetics, Texas Biomedical Research Institute, PO Box 760549, San Antonio, TX, USA
| | - Joanne E Curran
- Department of Genetics, Texas Biomedical Research Institute, PO Box 760549, San Antonio, TX, USA
| | - Jack W Kent
- Department of Genetics, Texas Biomedical Research Institute, PO Box 760549, San Antonio, TX, USA
| | - Melanie A Carless
- Department of Genetics, Texas Biomedical Research Institute, PO Box 760549, San Antonio, TX, USA
| | - Thomas D Dyer
- Department of Genetics, Texas Biomedical Research Institute, PO Box 760549, San Antonio, TX, USA
| | - Eugene I Drigalenko
- Department of Genetics, Texas Biomedical Research Institute, PO Box 760549, San Antonio, TX, USA
| | - Rene L Olvera
- Department of Psychiatry, University of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, USA
| | - Peter T Fox
- Research Imaging Institute, University of Texas Health Science Center San Antonio, 8403 Floyd Curl Drive, San Antonio, TX, USA; South Texas Veterans Health System, 7400 Merton Minter, San Antonio, TX 78229, USA
| | - Laura Almasy
- Department of Genetics, Texas Biomedical Research Institute, PO Box 760549, San Antonio, TX, USA
| | - Ravi Duggirala
- Department of Genetics, Texas Biomedical Research Institute, PO Box 760549, San Antonio, TX, USA
| | - Peter Kochunov
- Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA
| | - John Blangero
- Department of Genetics, Texas Biomedical Research Institute, PO Box 760549, San Antonio, TX, USA
| | - David C Glahn
- Department of Psychiatry, Yale University School of Medicine, 300 George Street, New Haven, CT, USA; Olin Neuropsychiatry Research Center, Institute of Living, Hartford Hospital, 200 Retreat Avenue, CT, USA
| |
Collapse
|
39
|
de Zwarte SMC, Johnston JAY, Cox Lippard ET, Blumberg HP. Frontotemporal White Matter in Adolescents with, and at-Risk for, Bipolar Disorder. J Clin Med 2014; 3:233-54. [PMID: 26237259 PMCID: PMC4449671 DOI: 10.3390/jcm3010233] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Revised: 02/13/2014] [Accepted: 02/17/2014] [Indexed: 12/13/2022] Open
Abstract
Frontotemporal neural systems are highly implicated in the emotional dysregulation characteristic of bipolar disorder (BD). Convergent genetic, postmortem, behavioral and neuroimaging evidence suggests abnormalities in the development of frontotemporal white matter (WM) in the pathophysiology of BD. This review discusses evidence for the involvement of abnormal WM development in BD during adolescence, with a focus on frontotemporal WM. Findings from diffusion tensor imaging (DTI) studies in adults and adolescents are reviewed to explore possible progressive WM abnormalities in the disorder. Intra- and interhemispheric frontotemporal abnormalities were reported in adults with BD. Although evidence in children and adolescents with BD to date has been limited, similar intrahemispheric and interhemispheric findings have also been reported. The findings in youths suggest that these abnormalities may represent a trait marker present early in the course of BD. Functional connectivity studies, demonstrating a relationship between WM abnormalities and frontotemporal dysfunction in BD, and DTI studies of vulnerability in first-degree relatives of individuals with BD, are discussed. Together, findings suggest the involvement of abnormal frontotemporal WM development in the pathophysiology of BD and that these abnormalities may be early trait markers of vulnerability; however, more studies are critically needed.
Collapse
Affiliation(s)
- Sonja M C de Zwarte
- Department of Psychiatry, Yale School of Medicine, 300 George Street, Suite 901, New Haven, CT 06511, USA.
| | - Jennifer A Y Johnston
- Department of Psychiatry, Yale School of Medicine, 300 George Street, Suite 901, New Haven, CT 06511, USA.
| | - Elizabeth T Cox Lippard
- Department of Psychiatry, Yale School of Medicine, 300 George Street, Suite 901, New Haven, CT 06511, USA.
| | - Hilary P Blumberg
- Department of Psychiatry, Yale School of Medicine, 300 George Street, Suite 901, New Haven, CT 06511, USA.
- Department of Diagnostic Radiology, Yale School of Medicine, New Haven, CT 06511, USA.
- Child Study Center, Yale School of Medicine, New Haven, CT 06511, USA.
| |
Collapse
|
40
|
Marlinge E, Bellivier F, Houenou J. White matter alterations in bipolar disorder: potential for drug discovery and development. Bipolar Disord 2014; 16:97-112. [PMID: 24571279 DOI: 10.1111/bdi.12135] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2012] [Accepted: 05/24/2013] [Indexed: 12/15/2022]
Abstract
OBJECTIVES Brain white matter (WM) alterations have recently emerged as potentially relevant in bipolar disorder. New techniques such as diffusion tensor imaging allow precise exploration of these WM microstructural alterations in bipolar disorder. Our objective was to critically review WM alterations in bipolar disorder, using neuroimaging and neuropathological studies, in the context of neural models and the potential for drug discovery and development. METHODS We conducted a systematic PubMed and Google Scholar search of the WM and bipolar disorder literature up to and including January 2013. RESULTS Findings relating to WM alterations are consistent in neuroimaging and neuropathology studies of bipolar disorder, especially in regions involved in emotional processing such as the anterior frontal lobe, corpus callosum, cingulate cortex, and in fronto-limbic connections. Some of the structural alterations are related to genetic risk factors for bipolar disorder and may underlie the dysfunctional emotional processing described in recent neurobiological models of bipolar disorder. Medication effects in bipolar disorder, from lithium and other mood stabilizers, might impact myelinating processes, particularly by inhibition of glycogen synthase kinase-3 beta. CONCLUSIONS Pathways leading to WM alterations in bipolar disorder represent potential targets for the development and discovery of new drugs. Myelin damage in bipolar disorder suggests that the effects of existing pro-myelinating drugs should also be evaluated to improve our understanding and treatment of this disease.
Collapse
Affiliation(s)
- Emeline Marlinge
- AP-HP, Groupe Henri Mondor-Albert Chenevier, Pôle de Psychiatrie, Paris, France; Inserm, U955, Equipe 15 (Psychiatrie Génétique), Paris, France; Fondation Fondamental, Créteil, France; Neurospin, I2BM, CEA, Gif-Sur-Yvette, France
| | | | | |
Collapse
|
41
|
Nickl-Jockschat T, Stöcker T, Krug A, Markov V, Huang R, Schneider F, Habel U, Eickhoff SB, Zerres K, Nöthen MM, Treutlein J, Rietschel M, Shah NJ, Kircher T. A Neuregulin-1 schizophrenia susceptibility variant causes perihippocampal fiber tract anomalies in healthy young subjects. Brain Behav 2014; 4:215-26. [PMID: 24683514 PMCID: PMC3967537 DOI: 10.1002/brb3.203] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2013] [Revised: 11/05/2013] [Accepted: 11/24/2013] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Changes in fiber tract architecture have gained attention as a potentially important aspect of schizophrenia neuropathology. Although the exact pathogenesis of these abnormalities yet remains to be elucidated, a genetic component is highly likely. Neuregulin-1 (NRG1) is one of the best-validated schizophrenia susceptibility genes. We here report the impact of the Neuregulin-1 rs35753505 variant on white matter structure in healthy young individuals with no family history of psychosis. METHODS We compared fractional anisotropy in 54 subjects that were either homozygous for the risk C allele carriers (n = 31) for rs35753505 or homozygous for the T allele (n = 23) using diffusion tensor imaging with 3T. Tract-Based Spatial Statistics (TBSS), a method especially developed for diffusion data analysis, was used to improve white matter registration and to focus the statistical analysis to major fiber tracts. RESULTS Statistical analysis showed that homozygous risk C allele carriers featured elevated fractional anisotropy (FA) in the right perihippocampal region and the white matter proximate to the left area 4p as well as the right hemisphere of the cerebellum. We found three clusters of reduced FA values in homozygous C allele carriers: in the left superior parietal region, the right prefrontal white matter and in the deep white matter of the left frontal lobe. CONCLUSION Our results highlight the importance of Neuregulin-1 for structural connectivity of the right medial temporal lobe. This finding is in line with well known neuropathological findings in this region in patients with schizophrenia.
Collapse
Affiliation(s)
- Thomas Nickl-Jockschat
- Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen UniversityAachen, Germany
- Juelich Aachen Research Alliance – Translational Brain MedicineJuelich/Aachen, Germany
- Correspondence Thomas Nickl-Jockschat, Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Pauwelsstrasse-30-, D-52074 Aachen, Germany. Tel: 0049-241/80-36413;, Fax: 0049-241/80-82401;, E-mail:
| | - Tony Stöcker
- Juelich Aachen Research Alliance – Translational Brain MedicineJuelich/Aachen, Germany
- Institute of Neurosciences and Medicine-4, Juelich Research CenterJuelich, Germany
| | - Axel Krug
- Department of Psychiatry and Psychotherapy, University of MarburgMarburg, Germany
| | - Valentin Markov
- Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen UniversityAachen, Germany
| | - Ruiwang Huang
- Juelich Aachen Research Alliance – Translational Brain MedicineJuelich/Aachen, Germany
- Institute of Neurosciences and Medicine-4, Juelich Research CenterJuelich, Germany
| | - Frank Schneider
- Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen UniversityAachen, Germany
- Juelich Aachen Research Alliance – Translational Brain MedicineJuelich/Aachen, Germany
| | - Ute Habel
- Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen UniversityAachen, Germany
- Juelich Aachen Research Alliance – Translational Brain MedicineJuelich/Aachen, Germany
| | - Simon B Eickhoff
- Institute of Clinical Neuroscience and Medical Psychology, Heinrich Heine UniversityDüsseldorf, Germany
- Department of Neuroscience und Medicine, INM-1, Research Center JülichJülich, Germany
| | - Klaus Zerres
- Institute of Human Genetics, RWTH Aachen UniversityAachen, Germany
| | - Markus M Nöthen
- Department of Genomics, Life and Brain Center, University of BonnBonn, Germany
| | - Jens Treutlein
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental HealthMannheim, Germany
| | - Marcella Rietschel
- Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental HealthMannheim, Germany
| | - Nadim Jon Shah
- Juelich Aachen Research Alliance – Translational Brain MedicineJuelich/Aachen, Germany
- Institute of Neurosciences and Medicine-4, Juelich Research CenterJuelich, Germany
- Department of Neurology, RWTH Aachen UniversityAachen, Germany
| | - Tilo Kircher
- Department of Psychiatry and Psychotherapy, University of MarburgMarburg, Germany
| |
Collapse
|
42
|
Abstract
Recently, there has been a wealth of research into structural and functional brain connectivity, and how they change over development. While we are far from a complete understanding, these studies have yielded important insights into human brain development. There is an ever growing variety of methods for assessing connectivity, each with its own advantages. Here we review research on the development of structural and/or functional brain connectivity in both typically developing subjects and subjects with neurodevelopmental disorders. Space limitations preclude an exhaustive review of brain connectivity across all developmental disorders, so we review a representative selection of recent findings on brain connectivity in autism, Fragile X, 22q11.2 deletion syndrome, Williams syndrome, Turner syndrome, and ADHD. Major strides have been made in understanding the developmental trajectory of the human connectome, offering insight into characteristic features of brain development and biological processes involved in developmental brain disorders. We also discuss some common themes, including hemispheric specialization - or asymmetry - and sex differences. We conclude by discussing some promising future directions in connectomics, including the merger of imaging and genetics, and a deeper investigation of the relationships between structural and functional connectivity.
Collapse
Affiliation(s)
- Emily L Dennis
- Imaging Genetics Center, Laboratory of Neuro Imaging, UCLA School of Medicine, 635 Charles Young Drive South, Suite 225, Los Angeles, CA 90095-7334, USA.
| | - Paul M Thompson
- Imaging Genetics Center, Laboratory of Neuro Imaging, UCLA School of Medicine, 635 Charles Young Drive South, Suite 225, Los Angeles, CA 90095-7334, USA
| |
Collapse
|
43
|
Roussos P, Haroutunian V. Schizophrenia: susceptibility genes and oligodendroglial and myelin related abnormalities. Front Cell Neurosci 2014; 8:5. [PMID: 24478629 PMCID: PMC3896818 DOI: 10.3389/fncel.2014.00005] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2013] [Accepted: 01/06/2014] [Indexed: 12/29/2022] Open
Abstract
Given that the genetic risk for schizophrenia is highly polygenic and the effect sizes, even for rare or de novo events, are modest at best, it has been suggested that multiple biological pathways are likely to be involved in the etiopathogenesis of the disease. Most efforts in understanding the cellular basis of schizophrenia have followed a “neuron-centric” approach, focusing on alterations in neurotransmitter systems and synapse cytoarchitecture. However, multiple lines of evidence coming from genetics and systems biology approaches suggest that apart from neurons, oligodendrocytes and potentially other glia are affected from schizophrenia risk loci. Neurobiological abnormalities linked with genetic association signal could identify abnormalities that are more likely to be primary, versus environmentally induced changes or downstream events. Here, we summarize genetic data that support the involvement of oligodendrocytes in schizophrenia, providing additional evidence for a causal role with the disease. Given the undeniable evidence of both neuronal and glial abnormalities in schizophrenia, we propose a neuro-glial model that invokes abnormalities at the node of Ranvier as a functional unit in the etiopathogenesis of the disease.
Collapse
Affiliation(s)
- Panos Roussos
- Mental Illness Research, Education, and Clinical Center (VISN 3), James J. Peters VA Medical Center Bronx, NY, USA ; Department of Psychiatry, Icahn School of Medicine at Mount Sinai New York, NY, USA ; Department of Genetics and Genomic Science and Institute for Multiscale Biology, Icahn School of Medicine at Mount Sinai New York, NY, USA
| | - Vahram Haroutunian
- Mental Illness Research, Education, and Clinical Center (VISN 3), James J. Peters VA Medical Center Bronx, NY, USA ; Department of Psychiatry, Icahn School of Medicine at Mount Sinai New York, NY, USA ; Department of Neuroscience, Icahn School of Medicine at Mount Sinai New York, NY, USA
| |
Collapse
|
44
|
Redpath HL, Lawrie SM, Sprooten E, Whalley HC, McIntosh AM, Hall J. Progress in imaging the effects of psychosis susceptibility gene variants. Expert Rev Neurother 2014; 13:37-47. [DOI: 10.1586/ern.12.145] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
45
|
Díez A, Cieza-Borrella C, Suazo V, González-Sarmiento R, Papiol S, Molina V. Cognitive outcome and gamma noise power unrelated to neuregulin 1 and 3 variation in schizophrenia. Ann Gen Psychiatry 2014; 13:18. [PMID: 24976857 PMCID: PMC4065086 DOI: 10.1186/1744-859x-13-18] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/17/2013] [Accepted: 05/29/2014] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND Neuregulins are a family of signalling proteins that orchestrate a broad range of cellular responses. Four genes encoding Neuregulins 1-4 have been identified so far in vertebrates. Among them, Neuregulin 1 and Neuregulin 3 have been reported to contribute to an increased risk for developing schizophrenia. We hypothesized that three specific variants of these genes (rs6994992 and rs3924999 for Neuregulin 1 and rs10748842 for Neuregulin 3) that have been related to this illness may modify information processing capacity in the cortex, which would be reflected in electrophysiological parameters (P3b amplitude or gamma noise power) and/or cognitive performance. METHODS We obtained DNA from 31 patients with schizophrenia and 23 healthy controls and analyzed NRG1 rs6994992, NRG1 rs3924999 and NRG3 rs10748842 promoter polymorphisms by allelic discrimination with real-time polymerase chain reaction (PCR). We compared cognitive outcome, P300 amplitude parameters and an electroencephalographic measure of noise power in the gamma band between the groups dichotomized according to genotype. RESULTS Contrary to our hypothesis, we could not detect any significant influence of variation in Neuregulin 1/Neuregulin 3 polymorphisms on cognitive performance or electrophysiological parameters of patients with schizophrenia. CONCLUSIONS Despite our findings, we cannot discard that other genetic variants and, more likely, interactions between those variants and with genetic variation related to different pathways may still influence cerebral processing in schizophrenia.
Collapse
Affiliation(s)
- Alvaro Díez
- Division of Psychiatry, Faculty of Brain Sciences, University College London, London W1W 7EJ, UK
| | - Clara Cieza-Borrella
- Institute of Biomedical Research of Salamanca (IBSAL), Salamanca 37007, Spain ; Molecular Medicine Unit, Department of Medicine and Institute of Molecular and Cellular Cancer Biology (IBMCC), University of Salamanca & CSIC, Salamanca 37007, Spain
| | - Vanessa Suazo
- Institute of Biomedical Research of Salamanca (IBSAL), Salamanca 37007, Spain ; Neuroscience Institute of Castilla y León (INCYL), University of Salamanca, Salamanca 37007, Spain
| | - Rogelio González-Sarmiento
- Institute of Biomedical Research of Salamanca (IBSAL), Salamanca 37007, Spain ; Molecular Medicine Unit, Department of Medicine and Institute of Molecular and Cellular Cancer Biology (IBMCC), University of Salamanca & CSIC, Salamanca 37007, Spain
| | - Sergi Papiol
- Anthropology Unit, Animal Biology Department, University of Barcelona, Barcelona 08028, Spain ; Clinical Neuroscience Section, Max Planck Institute of Experimental Medicine, Göttingen 37075, Germany
| | - Vicente Molina
- Institute of Biomedical Research of Salamanca (IBSAL), Salamanca 37007, Spain ; Neuroscience Institute of Castilla y León (INCYL), University of Salamanca, Salamanca 37007, Spain ; Psychiatry Department, School of Medicine, University of Valladolid, Valladolid 47005, Spain ; Psychiatry Service, University Hospital of Valladolid, Avenida Ramón y Cajal, 7, Valladolid 47005, Spain
| |
Collapse
|
46
|
Jahanshad N, Rajagopalan P, Thompson PM. Neuroimaging, nutrition, and iron-related genes. Cell Mol Life Sci 2013; 70:4449-61. [PMID: 23817740 PMCID: PMC3827893 DOI: 10.1007/s00018-013-1369-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2013] [Revised: 04/23/2013] [Accepted: 05/13/2013] [Indexed: 02/08/2023]
Abstract
Several dietary factors and their genetic modifiers play a role in neurological disease and affect the human brain. The structural and functional integrity of the living brain can be assessed using neuroimaging, enabling large-scale epidemiological studies to identify factors that help or harm the brain. Iron is one nutritional factor that comes entirely from our diet, and its storage and transport in the body are under strong genetic control. In this review, we discuss how neuroimaging can help to identify associations between brain integrity, genetic variations, and dietary factors such as iron. We also review iron's essential role in cognition, and we note some challenges and confounds involved in interpreting links between diet and brain health. Finally, we outline some recent discoveries regarding the genetics of iron and its effects on the brain, suggesting the promise of neuroimaging in revealing how dietary factors affect the brain.
Collapse
Affiliation(s)
- Neda Jahanshad
- Imaging Genetics Center, Laboratory of Neuro Imaging, Department of Neurology, UCLA School of Medicine, Neuroscience Research Building 225E, 635 Charles Young Drive, Los Angeles, CA 90095-1769 USA
| | - Priya Rajagopalan
- Imaging Genetics Center, Laboratory of Neuro Imaging, Department of Neurology, UCLA School of Medicine, Neuroscience Research Building 225E, 635 Charles Young Drive, Los Angeles, CA 90095-1769 USA
| | - Paul M. Thompson
- Imaging Genetics Center, Laboratory of Neuro Imaging, Department of Neurology, UCLA School of Medicine, Neuroscience Research Building 225E, 635 Charles Young Drive, Los Angeles, CA 90095-1769 USA
| |
Collapse
|
47
|
Jiang T, Zhou Y, Liu B, Liu Y, Song M. Brainnetome-wide association studies in schizophrenia: The advances and future. Neurosci Biobehav Rev 2013; 37:2818-35. [DOI: 10.1016/j.neubiorev.2013.10.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2012] [Revised: 10/07/2013] [Accepted: 10/09/2013] [Indexed: 12/21/2022]
|
48
|
The impact of a CACNA1C gene polymorphism on learning and hippocampal formation in healthy individuals: a diffusion tensor imaging study. Neuroimage 2013; 89:256-61. [PMID: 24269271 DOI: 10.1016/j.neuroimage.2013.11.030] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2013] [Revised: 11/09/2013] [Accepted: 11/14/2013] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Genome-wide association studies have identified the CACNA1C single nucleotide polymorphism (SNP) rs1006737 as one of the most consistent genetic findings as susceptibility locus for major psychiatric disorders. Furthermore, animal and genetic imaging studies have reported strong functional evidence for the association of CACNA1C with learning, memory, neural plasticity, and its association with the hippocampal formation. In the present study we investigated the impact of the CACNA1C SNP rs1006737 on the fractional anisotropy (FA) in the hippocampal formation as well as on verbal learning and memory in healthy individuals. METHODS 118 healthy individuals (72 males, 46 females, age 18-56years) initially underwent diffusion tensor imaging (DTI), 100 of them were included in the final analysis. We used Tract-Based Spatial Statistics (TBSS) to examine the impact of the CACNA1C SNP rs1006737 on the hippocampal formation as predefined region of interest (ROI). Furthermore, all participants completed the Verbal Learning and Memory Test (VLMT). RESULTS In the VLMT genotype was significantly associated with learning performance. Bonferroni corrected post-hoc tests indicated a diminished performance at the beginning of the learning curve in risk allele carriers compared to non-risk allele carriers. The TBSS ROI analysis revealed one cluster of reduced FA in risk allele carriers compared to non-risk allele carriers located in the right hippocampal formation. Moreover, an association between the initial learning performance and FA values was found. DISCUSSION These findings demonstrate that genetic variation in the CACNA1C SNP rs1006737 is associated with FA reduction in the hippocampal formation as well as with differences in learning performance in healthy individuals.
Collapse
|
49
|
Dennis EL, Thompson PM. Mapping connectivity in the developing brain. Int J Dev Neurosci 2013; 31:525-42. [PMID: 23722009 PMCID: PMC3800504 DOI: 10.1016/j.ijdevneu.2013.05.007] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2012] [Accepted: 05/14/2013] [Indexed: 02/07/2023] Open
Abstract
Recently, there has been a wealth of research into structural and functional brain connectivity, and how they change over development. While we are far from a complete understanding, these studies have yielded important insights into human brain development. There is an ever growing variety of methods for assessing connectivity, each with its own advantages. Here we review research on the development of structural and/or functional brain connectivity in both typically developing subjects and subjects with neurodevelopmental disorders. Space limitations preclude an exhaustive review of brain connectivity across all developmental disorders, so we review a representative selection of recent findings on brain connectivity in autism, Fragile X, 22q11.2 deletion syndrome, Williams syndrome, Turner syndrome, and ADHD. Major strides have been made in understanding the developmental trajectory of the human connectome, offering insight into characteristic features of brain development and biological processes involved in developmental brain disorders. We also discuss some common themes, including hemispheric specialization - or asymmetry - and sex differences. We conclude by discussing some promising future directions in connectomics, including the merger of imaging and genetics, and a deeper investigation of the relationships between structural and functional connectivity.
Collapse
Affiliation(s)
- Emily L Dennis
- Imaging Genetics Center, Laboratory of Neuro Imaging, UCLA School of Medicine, 635 Charles Young Drive South, Suite 225, Los Angeles, CA 90095-7334, USA.
| | | |
Collapse
|
50
|
Thermenos HW, Keshavan MS, Juelich RJ, Molokotos E, Whitfield-Gabrieli S, Brent BK, Makris N, Seidman LJ. A review of neuroimaging studies of young relatives of individuals with schizophrenia: a developmental perspective from schizotaxia to schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2013; 162B:604-35. [PMID: 24132894 DOI: 10.1002/ajmg.b.32170] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2013] [Accepted: 04/24/2013] [Indexed: 11/08/2022]
Abstract
In an effort to identify the developing abnormalities preceding psychosis, Dr. Ming T. Tsuang and colleagues at Harvard expanded Meehl's concept of "schizotaxia," and examined brain structure and function in families affected by schizophrenia (SZ). Here, we systematically review genetic (familial) high-risk (HR) studies of SZ using magnetic resonance imaging (MRI), examine how findings inform models of SZ etiology, and suggest directions for future research. Neuroimaging studies of youth at HR for SZ through the age of 30 were identified through a MEDLINE (PubMed) search. There is substantial evidence of gray matter volume abnormalities in youth at HR compared to controls, with an accelerated volume reduction over time in association with symptoms and cognitive deficits. In structural neuroimaging studies, prefrontal cortex (PFC) alterations were the most consistently reported finding in HR. There was also consistent evidence of smaller hippocampal volume. In functional studies, hyperactivity of the right PFC during performance of diverse tasks with common executive demands was consistently reported. The only longitudinal fMRI study to date revealed increasing left middle temporal activity in association with the emergence of psychotic symptoms. There was preliminary evidence of cerebellar and default mode network alterations in association with symptoms. Brain abnormalities in structure, function and neurochemistry are observed in the premorbid period in youth at HR for SZ. Future research should focus on the genetic and environmental contributions to these alterations, determine how early they emerge, and determine whether they can be partially or fully remediated by innovative treatments.
Collapse
Affiliation(s)
- H W Thermenos
- Harvard Medical School, Boston, Massachusetts; Massachusetts Mental Health Center, Division of Public Psychiatry, Boston, Massachusetts; Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
| | | | | | | | | | | | | | | |
Collapse
|